[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 31836
1. Mitchell G, Girgis A, Jiwa M, Sibbritt D, Burridge L: A GP Caregiver Needs Toolkit versus usual care in the management of the needs of caregivers of patients with advanced cancer: a randomized controlled trial. Trials; 2010;11:115
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A GP Caregiver Needs Toolkit versus usual care in the management of the needs of caregivers of patients with advanced cancer: a randomized controlled trial.
  • BACKGROUND: Caring for a person with progressive cancer creates challenges for caregivers.
  • This paper outlines a study protocol aimed at developing and evaluating the effectiveness of a general practice-based intervention to better meet the needs of caregivers of patients with advanced cancer.
  • METHODS/DESIGN: Two hundred and sixty caregivers will be randomised into each of two arms of the intervention (520 participants in total) through patients with advanced cancer attending medical and radiation oncology outpatient clinics at two tertiary hospital sites.
  • DISCUSSION: This study will determine whether systematic assessment of caregiver needs supported by caregiver-specific information for General Practitioners is effective in alleviating the unmet needs experienced by caregivers caring for patients with advanced cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pain Symptom Manage. 1999 Jun;17(6):418-28 [10388247.001]
  • [Cites] J Palliat Med. 2003 Dec;6(6):911-8 [14733683.001]
  • [Cites] Palliat Med. 2005 Oct;19(7):551-5 [16295288.001]
  • [Cites] Eur J Cancer Care (Engl). 2006 May;15(2):163-71 [16643264.001]
  • [Cites] Palliat Med. 2008 Dec;22(8):904-12 [18772208.001]
  • [Cites] Palliat Med. 2008 Dec;22(8):956-64 [18952754.001]
  • [Cites] J Eval Clin Pract. 2009 Aug;15(4):602-6 [19522727.001]
  • [Cites] Psychooncology. 2010 Jul;19(7):726-33 [19777532.001]
  • [Cites] Palliat Med. 2003 Jan;17(1):63-74 [12597468.001]
  • [Cites] Palliat Med. 2003 Jan;17(1):27-39 [12597463.001]
  • [Cites] J Pain Symptom Manage. 2002 Aug;24(2):91-6 [12231124.001]
  • [Cites] Hematol Oncol Clin North Am. 2002 Jun;16(3):745-62, xi [12170579.001]
  • [Cites] J Clin Oncol. 2001 Jul 1;19(13):3219-25 [11432889.001]
  • [Cites] Cancer. 2000 Jan 1;88(1):217-25 [10618626.001]
  • [Cites] Palliat Med. 1994;8(3):183-96 [7952369.001]
  • [Cites] Acta Psychiatr Scand. 1983 Jun;67(6):361-70 [6880820.001]
  • [Cites] CMAJ. 2004 Jun 8;170(12):1795-801 [15184333.001]
  • [Cites] J Palliat Med. 2004 Feb;7(1):19-25 [15008126.001]
  • [Cites] Psychooncology. 2011 Apr;20(4):387-93 [20878835.001]
  • [Cites] Med Care. 2003 Aug;41(8):992-1001 [12886178.001]
  • [Cites] Psychooncology. 2005 Jun;14(6):492-502 [15452896.001]
  • (PMID = 21114863.001).
  • [ISSN] 1745-6215
  • [Journal-full-title] Trials
  • [ISO-abbreviation] Trials
  • [Language] eng
  • [Databank-accession-numbers] ISRCTN/ ISRCTN43614355
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3009964
  •  go-up   go-down


2. Macciò A, Madeddu C, Gramignano G, Mulas C, Sanna E, Mantovani G: Efficacy and safety of oral lactoferrin supplementation in combination with rHuEPO-beta for the treatment of anemia in advanced cancer patients undergoing chemotherapy: open-label, randomized controlled study. Oncologist; 2010;15(8):894-902
MedlinePlus Health Information. consumer health - Anemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and safety of oral lactoferrin supplementation in combination with rHuEPO-beta for the treatment of anemia in advanced cancer patients undergoing chemotherapy: open-label, randomized controlled study.
  • Advanced-stage cancer patients often suffer from anemia that closely resembles the anemia of chronic inflammatory diseases characterized by specific changes in iron homeostasis and absorption. i.v. iron improves the efficacy of recombinant human erythropoietin (rHuEPO) in anemic cancer patients undergoing chemotherapy.
  • We report the results of an open-label, randomized, prospective trial aimed at testing the efficacy and safety of treatment with oral lactoferrin versus i.v. iron, both combined with rHuEPO, for the treatment of anemia in a population of 148 advanced cancer patients undergoing chemotherapy.
  • In conclusion, these results show similar efficacy for oral lactoferrin and for i.v. iron, combined with rHuEPO, for the treatment of anemia in advanced cancer patients undergoing chemotherapy.

  • Genetic Alliance. consumer health - Anemia.
  • Genetic Alliance. consumer health - Oral cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2009 May 2;373(9674):1532-42 [19410717.001]
  • [Cites] Biochem Pharmacol. 2009 May 15;77(10):1572-9 [19174153.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2840-6 [10561360.001]
  • [Cites] Cancer. 2001 Jun 15;91(12):2214-21 [11413508.001]
  • [Cites] Haematologica. 2002 Nov;87(11):1209-21 [12414352.001]
  • [Cites] Blood. 2003 Aug 1;102(3):783-8 [12663437.001]
  • [Cites] Lancet. 2003 Oct 18;362(9392):1255-60 [14575968.001]
  • [Cites] Semin Oncol. 2003 Oct;30(5 Suppl 16):174-84 [14613039.001]
  • [Cites] Am J Med. 2004 Apr 5;116 Suppl 7A:11S-26S [15050883.001]
  • [Cites] J Clin Oncol. 2004 Apr 1;22(7):1301-7 [15051778.001]
  • [Cites] J Clin Invest. 2004 May;113(9):1251-3 [15124013.001]
  • [Cites] Int J Cancer. 2004 Sep 1;111(3):398-403 [15221967.001]
  • [Cites] Biometals. 2004 Jun;17(3):209-16 [15222467.001]
  • [Cites] N Engl J Med. 1990 Jun 14;322(24):1689-92 [2342534.001]
  • [Cites] Blood. 1992 Oct 1;80(7):1639-47 [1391934.001]
  • [Cites] J Natl Cancer Inst. 1999 Oct 6;91(19):1616-34 [10511589.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):1011-23 [15758012.001]
  • [Cites] Blood. 2005 Jul 1;106(1):362-7 [15774616.001]
  • [Cites] Oncologist. 2005 Jun-Jul;10(6):438-48 [15967837.001]
  • [Cites] Nat Rev Cancer. 2005 Jul;5(7):543-55 [15965494.001]
  • [Cites] Stem Cells Dev. 2005 Oct;14(5):548-55 [16305339.001]
  • [Cites] Am J Clin Nutr. 2006 Feb;83(2):305-9 [16469988.001]
  • [Cites] Oncologist. 2007 Feb;12(2):231-42 [17296819.001]
  • [Cites] Clin Cancer Res. 2007 Mar 1;13(5):1601-10 [17332307.001]
  • [Cites] Lancet. 2007 May 5;369(9572):1502-4 [17482969.001]
  • [Cites] J Clin Oncol. 2008 Jan 1;26(1):132-49 [17954713.001]
  • [Cites] JAMA. 2008 Feb 27;299(8):914-24 [18314434.001]
  • [Cites] J Clin Oncol. 2008 Apr 1;26(10):1611-8 [18375890.001]
  • [Cites] J Clin Oncol. 2008 Apr 1;26(10):1619-25 [18375891.001]
  • [Cites] J Natl Compr Canc Netw. 2008 Jul;6(6):536-64 [18597709.001]
  • [Cites] Cancer. 2008 Sep 15;113(6):1480-8 [18642348.001]
  • [Cites] Int J Antimicrob Agents. 2009 Apr;33(4):301.e1-8 [18842395.001]
  • [Cites] Semin Arthritis Rheum. 2009 Apr;38(5):382-8 [18336871.001]
  • [Cites] J Clin Oncol. 2009 Sep 1;27(25):4217-26 [19636005.001]
  • (PMID = 20647390.001).
  • [ISSN] 1549-490X
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ferric Compounds; 0 / Hemoglobins; 0 / Recombinant Proteins; 11096-26-7 / Erythropoietin; 88088-23-7 / ferric gluconate; EC 3.4.21.- / Lactoferrin
  • [Other-IDs] NLM/ PMC3228020
  •  go-up   go-down


3. Kadan-Lottick NS, Vanderwerker LC, Block SD, Zhang B, Prigerson HG: Psychiatric disorders and mental health service use in patients with advanced cancer: a report from the coping with cancer study. Cancer; 2005 Dec 15;104(12):2872-81
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Psychiatric disorders and mental health service use in patients with advanced cancer: a report from the coping with cancer study.
  • BACKGROUND: Psychological morbidity has been proposed as a source of distress in cancer patients.
  • 1) determine the prevalence of diagnosable psychiatric illnesses, and 2) describe the mental health services received and predictors of service utilization in patients with advanced cancer.
  • METHODS: This was a cross-sectional, multi-institutional study of 251 eligible patients with advanced cancer.
  • RESULTS: Overall, 12% met criteria for a major psychiatric condition and 28% had accessed a mental health intervention for a psychiatric illness since the cancer diagnosis.
  • Cancer patients who had discussed psychological concerns with mental health staff (odds ratio [OR] = 19.2; 95% confidence interval [95% CI], 8.90-41.50) and non-Hispanic white patients (OR = 2.7; 95% CI, 1.01-7.43) were more likely to receive mental health services in adjusted analysis.
  • CONCLUSIONS: Advanced cancer patients experience major psychiatric disorders at a prevalence similar to the general population, but affected individuals have a low rate of utilizing mental health services.

  • MedlinePlus Health Information. consumer health - Cancer--Living with Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 American Cancer Society.
  • [Cites] JAMA. 1983 Feb 11;249(6):751-7 [6823028.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):6899-907 [16129849.001]
  • [Cites] J Clin Oncol. 1985 Nov;3(11):1553-60 [4056846.001]
  • [Cites] Ann Intern Med. 1987 Oct;107(4):481-5 [3631786.001]
  • [Cites] Lancet. 1999 Oct 16;354(9187):1331-6 [10533861.001]
  • [Cites] Ann Intern Med. 2000 Feb 1;132(3):209-18 [10651602.001]
  • [Cites] Palliat Med. 1999 Jul;13(4):353-4 [10659105.001]
  • [Cites] Cancer. 2000 May 15;88(10):2398-424 [10820364.001]
  • [Cites] JAMA. 2000 Nov 15;284(19):2518-21 [11074786.001]
  • [Cites] JAMA. 2000 Dec 13;284(22):2907-11 [11147988.001]
  • [Cites] Ethn Dis. 2001 Winter;11(1):97-106 [11289258.001]
  • [Cites] Patient Educ Couns. 2001 Dec 1;45(3):195-8 [11722855.001]
  • [Cites] J Clin Psychiatry. 2001;62 Suppl 8:64-7 [12108825.001]
  • [Cites] Cancer. 2002 Jun 1;94(11):3006-15 [12115391.001]
  • [Cites] Hematol Oncol Clin North Am. 2002 Jun;16(3):671-700 [12170575.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2754-9 [12860955.001]
  • [Cites] Am J Hematol. 2003 Nov;74(3):224 [14587060.001]
  • [Cites] Semin Clin Neuropsychiatry. 2003 Oct;8(4):241-52 [14613051.001]
  • [Cites] Jpn J Clin Oncol. 2003 Oct;33(10):538-40 [14623924.001]
  • [Cites] Gen Hosp Psychiatry. 2004 Mar-Apr;26(2):121-8 [15038929.001]
  • [Cites] J Clin Oncol. 2004 May 15;22(10):1957-65 [15143090.001]
  • [Cites] J Cancer Res Clin Oncol. 2004 Jun;130(6):327-33 [15007642.001]
  • [Cites] J Natl Cancer Inst Monogr. 2004;(32):9-16 [15263035.001]
  • [Cites] J Natl Cancer Inst Monogr. 2004;(32):32-9 [15263039.001]
  • [Cites] J Natl Cancer Inst Monogr. 2004;(32):57-71 [15263042.001]
  • [Cites] J Natl Cancer Inst Monogr. 2004;(32):80-92 [15263046.001]
  • [Cites] J Natl Cancer Inst Monogr. 2004;(32):127-35 [15263054.001]
  • [Cites] Br J Cancer. 1991 Aug;64(2):349-52 [1892762.001]
  • [Cites] Int J Psychiatry Med. 1991;21(2):149-55 [1894454.001]
  • [Cites] Psychosomatics. 1991 Fall;32(4):420-5 [1961856.001]
  • [Cites] Arch Gen Psychiatry. 1992 Aug;49(8):630-6 [1637253.001]
  • [Cites] Eur J Cancer. 1993;29A(4):524-7 [8435204.001]
  • [Cites] Psychosomatics. 1993 May-Jun;34(3):208-21 [8493302.001]
  • [Cites] Palliat Med. 1993;7(3):213-8 [8261189.001]
  • [Cites] J Affect Disord. 1993 Oct-Nov;29(2-3):77-84 [8300980.001]
  • [Cites] Qual Life Res. 1994 Jun;3(3):183-9 [7920492.001]
  • [Cites] J Pain Symptom Manage. 1995 Feb;10(2):131-41 [7730685.001]
  • [Cites] Am J Psychiatry. 1995 Aug;152(8):1185-91 [7625468.001]
  • [Cites] N Engl J Med. 1996 Jul 18;335(3):172-8 [8657216.001]
  • [Cites] Soc Sci Med. 1996 Jun;42(11):1511-9 [8771634.001]
  • [Cites] Clin Geriatr Med. 1996 May;12(2):329-47 [8799351.001]
  • [Cites] Am J Psychiatry. 1997 Dec;154(12):1734-40 [9396954.001]
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1594-600 [9552071.001]
  • [Cites] Psychosomatics. 1998 Jul-Aug;39(4):366-70 [9691706.001]
  • [Cites] Oncol Nurs Forum. 1999 Apr;26(3):593-9 [10214600.001]
  • [Cites] Palliat Med. 1999 Jan;13(1):45-50 [10320875.001]
  • [Cites] Br J Cancer. 1999 May;80(5-6):766-74 [10360654.001]
  • [Cites] Support Care Cancer. 2004 Sep;12(9):657-62 [15185134.001]
  • [Cites] Support Care Cancer. 2004 Dec;12(12):864-70 [15480816.001]
  • [Cites] Cancer. 1984 May 15;53(10 Suppl):2243-9 [6704912.001]
  • (PMID = 16284994.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA106370; United States / NCRR NIH HHS / RR / K12 RR017594; United States / NIA NIH HHS / AG / P30AG21342; United States / NIMH NIH HHS / MH / MH63892; United States / NCRR NIH HHS / RR / K12RR17594; United States / NIA NIH HHS / AG / P30 AG021342; United States / NIMH NIH HHS / MH / MH56529; United States / NCI NIH HHS / CA / R01 CA106370; United States / NIMH NIH HHS / MH / R01 MH063892
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS8305; NLM/ PMC1459283
  •  go-up   go-down


Advertisement
4. Loprinzi CL, Levitt R, Barton DL, Sloan JA, Atherton PJ, Smith DJ, Dakhil SR, Moore DF Jr, Krook JE, Rowland KM Jr, Mazurczak MA, Berg AR, Kim GP, North Central Cancer Treatment Group: Evaluation of shark cartilage in patients with advanced cancer: a North Central Cancer Treatment Group trial. Cancer; 2005 Jul 1;104(1):176-82
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of shark cartilage in patients with advanced cancer: a North Central Cancer Treatment Group trial.
  • The basis for this popularity is the claim that sharks rarely get cancer because of the high proportion of cartilage in the shark's body.
  • Therefore, a clinical trial was conducted to look at the impact of shark cartilage in patients with advanced cancer.
  • The primary goal of this trial was to determine whether a shark cartilage product improved overall survival for patients with advanced cancer who were getting standard care.
  • CONCLUSION: This trial was unable to demonstrate any suggestion of efficacy for this shark cartilage product in patients with advanced cancer.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Complementary and Integrative Medicine.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15912493.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-25224; United States / NCI NIH HHS / CA / CA-35101; United States / NCI NIH HHS / CA / CA-35103; United States / NCI NIH HHS / CA / CA-35113; United States / NCI NIH HHS / CA / CA-35195; United States / NCI NIH HHS / CA / CA-35269; United States / NCI NIH HHS / CA / CA-35272; United States / NCI NIH HHS / CA / CA-35448; United States / NCI NIH HHS / CA / CA-37404; United States / NCI NIH HHS / CA / CA-37417; United States / NCI NIH HHS / CA / CA-52352; United States / NCI NIH HHS / CA / CA-60276; United States / NCI NIH HHS / CA / CA-63848; United States / NCI NIH HHS / CA / CA-63849
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Placebos; 0 / Tissue Extracts
  •  go-up   go-down


5. Hutton JL, Baracos VE, Wismer WV: Chemosensory dysfunction is a primary factor in the evolution of declining nutritional status and quality of life in patients with advanced cancer. J Pain Symptom Manage; 2007 Feb;33(2):156-65
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemosensory dysfunction is a primary factor in the evolution of declining nutritional status and quality of life in patients with advanced cancer.
  • Alterations in taste and smell functions have been reported in cancer patients.
  • Although these senses are known to be particularly affected by chemotherapy, many features of chemosensory perception in cancer patients remain obscure.
  • To assess this relationship, self-perceived taste and smell function were evaluated using a validated questionnaire in 66 patients with advanced cancer receiving palliative care (median survival 7.4 months).
  • Severe chemosensory dysfunction is persistent well beyond the window of active therapy in patients with advanced cancer and represents a primary factor relating to malnutrition, wasting, and poor QOL.
  • Further research is required to identify appropriate strategies to alleviate this important group of symptoms, to determine whether intervention will improve QOL, and to match foods and diet to the unique chemosensory profile of advanced cancer patients.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Taste and Smell Disorders.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17280921.001).
  • [ISSN] 0885-3924
  • [Journal-full-title] Journal of pain and symptom management
  • [ISO-abbreviation] J Pain Symptom Manage
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


6. Kutner JS, Smith MC, Corbin L, Hemphill L, Benton K, Mellis BK, Beaty B, Felton S, Yamashita TE, Bryant LL, Fairclough DL: Massage therapy versus simple touch to improve pain and mood in patients with advanced cancer: a randomized trial. Ann Intern Med; 2008 Sep 16;149(6):369-79
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Massage therapy versus simple touch to improve pain and mood in patients with advanced cancer: a randomized trial.
  • OBJECTIVE: To evaluate the efficacy of massage for decreasing pain and symptom distress and improving quality of life among persons with advanced cancer.
  • PATIENTS: 380 adults with advanced cancer who were experiencing moderate-to-severe pain; 90% were enrolled in hospice.
  • The generalizability to all patients with advanced cancer is uncertain.
  • CONCLUSION: Massage may have immediately beneficial effects on pain and mood among patients with advanced cancer.

  • MedlinePlus Health Information. consumer health - Pain.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Nurs. 2000 Oct;23(5):327-36 [11037952.001]
  • [Cites] AACN Clin Issues. 2000 Feb;11(1):77-96 [11040555.001]
  • [Cites] Cancer. 2000 Oct 15;89(8):1854-65 [11042583.001]
  • [Cites] J Pain Symptom Manage. 2000 Nov;20(5):374-87 [11068159.001]
  • [Cites] Stat Med. 2001 Apr 15;20(7):1009-21 [11276032.001]
  • [Cites] Hosp J. 2000;15(3):31-53 [11315685.001]
  • [Cites] Emerg Med J. 2001 May;18(3):205-7 [11354213.001]
  • [Cites] J Pain Symptom Manage. 2001 Jun;21(6):473-80 [11397605.001]
  • [Cites] Cancer Nurs. 2001 Jun;24(3):180-4 [11409061.001]
  • [Cites] Palliat Med. 2001 Sep;15(5):363-71 [11591087.001]
  • [Cites] Eur J Pharmacol. 2001 Oct 19;429(1-3):1-11 [11698022.001]
  • [Cites] Complement Ther Nurs Midwifery. 2000 Nov;6(4):169-75 [11858299.001]
  • [Cites] J Palliat Med. 2002 Jun;5(3):397-406 [12133244.001]
  • [Cites] Palliat Med. 2003 Jun;17(4):300-7 [12822844.001]
  • [Cites] J Pain. 2003 Sep;4(7):407-14 [14622683.001]
  • [Cites] Integr Cancer Ther. 2003 Dec;2(4):332-44 [14713325.001]
  • [Cites] Palliat Med. 2004 Mar;18(2):87-92 [15046404.001]
  • [Cites] Cochrane Database Syst Rev. 2004;(2):CD002287 [15106172.001]
  • [Cites] J Psychosom Res. 2004 Jul;57(1):45-52 [15256294.001]
  • [Cites] J Palliat Med. 2004 Jun;7(3):405-7 [15265348.001]
  • [Cites] Nurs Res. 1986 Mar-Apr;35(2):101-6 [3633503.001]
  • [Cites] Cancer. 1987 Sep 1;60(5):1151-8 [3300951.001]
  • [Cites] World Health Organ Tech Rep Ser. 1990;804:1-75 [1702248.001]
  • [Cites] Holist Nurs Pract. 1991 Oct;6(1):24-31 [1918182.001]
  • [Cites] Cancer Nurs. 1993 Apr;16(2):93-101 [8477405.001]
  • [Cites] Ann Acad Med Singapore. 1994 Mar;23(2):129-38 [8080219.001]
  • [Cites] Qual Life Res. 1994 Jun;3(3):183-9 [7920492.001]
  • [Cites] Eur J Cancer. 1994;30A(9):1326-36 [7999421.001]
  • [Cites] Pain. 1995 May;61(2):277-84 [7659438.001]
  • [Cites] Ann Emerg Med. 1996 Apr;27(4):485-9 [8604867.001]
  • [Cites] J Pain Symptom Manage. 1996 Oct;12(4):209-20 [8898504.001]
  • [Cites] J Pain Symptom Manage. 1996 Nov;12(5):273-82 [8942122.001]
  • [Cites] Neurology. 1997 Feb;48(2):332-8 [9040716.001]
  • [Cites] Palliat Med. 1997 Jan;11(1):3-20 [9068681.001]
  • [Cites] J Pain Symptom Manage. 1997 May;13(5):254-61 [9185430.001]
  • [Cites] Cancer. 1998 Jul 1;83(1):173-9 [9655308.001]
  • [Cites] Support Care Cancer. 1998 Nov;6(6):539-41 [9833305.001]
  • [Cites] Am Psychol. 1998 Dec;53(12):1270-81 [9872050.001]
  • [Cites] JAMA. 1999 Jan 13;281(2):163-8 [9917120.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):361-70 [10458255.001]
  • [Cites] Cancer Invest. 2004;22(4):526-36 [15565810.001]
  • [Cites] Cancer Invest. 2004;22(5):678-87 [15581048.001]
  • [Cites] Cancer Control. 2005 Jul;12(3):186-95 [16062166.001]
  • [Cites] Palliat Support Care. 2003 Sep;1(3):231-7 [16594423.001]
  • [Cites] J Holist Nurs. 2006 Sep;24(3):152-61 [16880409.001]
  • [Cites] Clin Nurs Res. 2007 May;16(2):85-99; discussion 100-2 [17452429.001]
  • [Cites] J Pain Symptom Manage. 2007 Sep;34(3):227-36 [17572055.001]
  • [Cites] Health Qual Life Outcomes. 2007;5:51 [17683554.001]
  • [Cites] Ann Intern Med. 2008 Feb 19;148(4):W60-6 [18283201.001]
  • [Cites] Ann Intern Med. 2008 Feb 19;148(4):295-309 [18283207.001]
  • [Cites] J Soc Integr Oncol. 2008 Winter;6(1):19-28 [18302907.001]
  • [Cites] J Soc Integr Oncol. 2007 Fall;5(4):139-46 [19087757.001]
  • [Cites] Pain. 1999 May;81(1-2):129-34 [10353500.001]
  • [Cites] J Pain Symptom Manage. 1999 Jul;18(1):9-16 [10439568.001]
  • [Cites] J Pain Symptom Manage. 2004 Sep;28(3):244-9 [15336336.001]
  • [Cites] ANS Adv Nurs Sci. 1982 Jul;4(4):44-61 [6808905.001]
  • [Cites] ANS Adv Nurs Sci. 1984 Jan;6(2):42-9 [6322674.001]
  • [Cites] Lancet. 1985 May 25;1(8439):1204-6 [2860399.001]
  • [Cites] BMJ. 2000 Feb 19;320(7233):513-4 [10678876.001]
  • [Cites] Cancer. 2000 Sep 1;89(5):1162-71 [10964347.001]
  • [SummaryForPatientsIn] Ann Intern Med. 2008 Sep 16;149(6):I38 [18794554.001]
  • (PMID = 18794556.001).
  • [ISSN] 1539-3704
  • [Journal-full-title] Annals of internal medicine
  • [ISO-abbreviation] Ann. Intern. Med.
  • [Language] ENG
  • [Grant] United States / NCCIH NIH HHS / AT / 1R01AT0100601A2; United States / NCCIH NIH HHS / AT / R01 AT001006; United States / NCCIH NIH HHS / AT / AT001006-02; United States / NCCIH NIH HHS / AT / R01 AT001006-01A2; United States / NCCIH NIH HHS / AT / AT001006-03; United States / NCCIH NIH HHS / AT / R01 AT001006-03; United States / NCCIH NIH HHS / AT / AT001006-01A2; United States / NCCIH NIH HHS / AT / R01 AT001006-02
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS65966; NLM/ PMC2631433
  •  go-up   go-down


7. Torres-Vigil I, Aday LA, Reyes-Gibby C, De Lima L, Herrera AP, Mendoza T, Cleeland CS: Health care providers' assessments of the quality of advanced-cancer care in Latin American medical institutions: a comparison of predictors in five countries: Argentina, Brazil, Cuba, Mexico, and Peru. J Pain Palliat Care Pharmacother; 2008;22(1):7-20
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Health care providers' assessments of the quality of advanced-cancer care in Latin American medical institutions: a comparison of predictors in five countries: Argentina, Brazil, Cuba, Mexico, and Peru.
  • This paper describes an innovative Pan-American survey on advanced-cancer care and examines the quality-of-care provided by Latin American institutions.
  • A convenience sample of 777 physicians and nurses who treat cancer patients in Argentina, Brazil, Cuba, Mexico, and Peru were surveyed.
  • Barring respondents from Cuba, providers from the other four nations who practice in public institutions rated the quality of advanced-cancer care in their own institutions lower than those practicing in private hospitals or specialized cancer centers.
  • Other institutional quality-of-care predictors included type of city, affordability-of-care ratings, availability of opioid analgesics, where patients die, barriers to cancer pain management, and the provider's specialty and gender.
  • These findings highlight the need for providing accessible care and services to improve the quality of advanced-cancer care in Latin American institutions.
  • Efforts should be aimed at improving the care offered in public institutions and addressing other types of disparities that may exist within countries by creating supportive and palliative cancer care programs that are accessible and affordable to those most in need.
  • [MeSH-minor] Argentina. Brazil. Cancer Care Facilities. Cuba. Disease Progression. Health Surveys. Hospitals, Private. Hospitals, Public. Humans. Latin America. Mexico. Peru. Practice Patterns, Physicians'

  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19042817.001).
  • [ISSN] 1536-0539
  • [Journal-full-title] Journal of pain & palliative care pharmacotherapy
  • [ISO-abbreviation] J Pain Palliat Care Pharmacother
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Gagnon B, Low G, Schreier G: Methylphenidate hydrochloride improves cognitive function in patients with advanced cancer and hypoactive delirium: a prospective clinical study. J Psychiatry Neurosci; 2005 Mar;30(2):100-7
Hazardous Substances Data Bank. METHYLPHENIDATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methylphenidate hydrochloride improves cognitive function in patients with advanced cancer and hypoactive delirium: a prospective clinical study.
  • OBJECTIVE: To investigate the clinical improvement observed in patients with advanced cancer and hypoactive delirium after the administration of methylphenidate hydrochloride.
  • METHODS: Fourteen patients with advanced cancer and hypoactive delirium were seen between March 1999 and August 2000 at the Palliative Care Day Hospital and the inpatient Tertiary Palliative Care Unit of Montreal General Hospital, Montreal.
  • CONCLUSIONS: Hypoactive delirium that cannot be explained by an underlying cause (metabolic or drug-induced) in patients with advanced cancer appears to be a specific syndrome that could be improved by the administration of methylphenidate.

  • MedlinePlus Health Information. consumer health - Cancer--Living with Cancer.
  • MedlinePlus Health Information. consumer health - Delirium.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Intern Med. 2000 Mar 27;160(6):786-94 [10737278.001]
  • [Cites] Rinsho Shinkeigaku. 1999 May;39(5):555-9 [10424149.001]
  • [Cites] Brain. 2000 Jul;123 ( Pt 7):1481-94 [10869059.001]
  • [Cites] Mayo Clin Proc. 2000 Jul;75(7):711-21 [10907387.001]
  • [Cites] J Pain Symptom Manage. 2000 Jun;19(6):412-26 [10908822.001]
  • [Cites] Eur J Nucl Med. 2000 Oct;27(10):1518-24 [11083541.001]
  • [Cites] J Neurosci. 2001 Feb 15;21(4):1413-9 [11160413.001]
  • [Cites] Am J Hosp Palliat Care. 2001 Nov-Dec;18(6):403-7 [11712722.001]
  • [Cites] J Clin Oncol. 2002 Jan 1;20(1):335-9 [11773187.001]
  • [Cites] J Neurosci. 2002 Oct 1;22(19):8705-10 [12351745.001]
  • [Cites] Ann Nucl Med. 2002 Dec;16(8):527-31 [12593417.001]
  • [Cites] Neurosci Biobehav Rev. 2003 Nov;27(7):615-21 [14624806.001]
  • [Cites] J Psychiatr Res. 1975 Nov;12(3):189-98 [1202204.001]
  • [Cites] Can J Psychiatry. 1984 Feb;29(1):46-9 [6704886.001]
  • [Cites] Head Neck Surg. 1986 Mar-Apr;8(4):296-300 [3744858.001]
  • [Cites] N Engl J Med. 1989 Mar 2;320(9):578-82 [2644535.001]
  • [Cites] J Pain Symptom Manage. 1989 Mar;4(1):3-6 [2703735.001]
  • [Cites] Am J Psychiatry. 1990 Jan;147(1):22-30 [2403472.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1990 Dec;53(12):1084-8 [1963440.001]
  • [Cites] Support Care Cancer. 1995 Mar;3(2):135-8 [7539701.001]
  • [Cites] Int J Psychiatry Med. 1995;25(1):1-19 [7649714.001]
  • [Cites] Int J Psychiatry Med. 1995;25(1):53-67 [7649718.001]
  • [Cites] Psychosomatics. 1995 Sep-Oct;36(5):471-9 [7568655.001]
  • [Cites] J Neuropsychiatry Clin Neurosci. 1995 Summer;7(3):347-50 [7580196.001]
  • [Cites] Psychosomatics. 1996 Jan-Feb;37(1):57-62 [8600496.001]
  • [Cites] JAMA. 1996 Mar 20;275(11):852-7 [8596223.001]
  • [Cites] Psychiatr Clin North Am. 1996 Sep;19(3):515-47 [8856815.001]
  • [Cites] Drug Saf. 1996 Oct;15(4):291-301 [8905254.001]
  • [Cites] Semin Oncol. 1997 Jun;24(3):318-28 [9208887.001]
  • [Cites] Brain. 1997 Jun;120 ( Pt 6):923-8 [9217677.001]
  • [Cites] Pathologe. 1997 Sep;18(5):406-10 [9432678.001]
  • [Cites] Neuropediatrics. 1998 Jun;29(3):159-62 [9706628.001]
  • [Cites] Arch Phys Med Rehabil. 1998 Sep;79(9):1047-50 [9749682.001]
  • [Cites] J Pain Symptom Manage. 1998 Sep;16(3):193-8 [9769622.001]
  • [Cites] Rev Neurol (Paris). 1998 Jul;154(6-7):539-41 [9773088.001]
  • [Cites] J Neurol. 1998 Nov;245(11):695-708 [9808237.001]
  • [Cites] N Engl J Med. 1999 Jun 10;340(23):1788-95 [10362822.001]
  • [Cites] J Formos Med Assoc. 1999 May;98(5):368-71 [10420707.001]
  • [Cites] Support Care Cancer. 2000 Mar;8(2):134-7 [10739361.001]
  • (PMID = 15798785.001).
  • [ISSN] 1180-4882
  • [Journal-full-title] Journal of psychiatry & neuroscience : JPN
  • [ISO-abbreviation] J Psychiatry Neurosci
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Central Nervous System Stimulants; 207ZZ9QZ49 / Methylphenidate
  • [Other-IDs] NLM/ PMC551162
  •  go-up   go-down


9. Sherman DW, Ye XY, McSherry C, Calabrese M, Parkas V, Gatto M: Spiritual well-being as a dimension of quality of life for patients with advanced cancer and AIDS and their family caregivers: results of a longitudinal study. Am J Hosp Palliat Care; 2005 Sep-Oct;22(5):349-62
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spiritual well-being as a dimension of quality of life for patients with advanced cancer and AIDS and their family caregivers: results of a longitudinal study.
  • Based on a longitudinal, quality-of-life study, this article presents pilot data regarding the spiritual well-being of patients with advanced cancer or AIDS and their family caregivers.


10. Orrevall Y, Tishelman C, Permert J: Home parenteral nutrition: a qualitative interview study of the experiences of advanced cancer patients and their families. Clin Nutr; 2005 Dec;24(6):961-70
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Home parenteral nutrition: a qualitative interview study of the experiences of advanced cancer patients and their families.
  • BACKGROUND & AIM: The benefit of home parenteral nutrition (HPN) to advanced cancer patients is often debated and an evidence-base for parenteral nutrition (PN) in palliative care is lacking.
  • The aim of this study is to investigate the experiences of HPN from the perspective of advanced cancer patients and their family members.
  • METHODS: Semi-structured interviews were conducted with 13 advanced cancer patients with experience of HPN and 11 family members.
  • Positive statements about HPN were often coupled to the benefits of being enrolled in advanced home care.
  • CONCLUSION: This study indicates that the interviewed cancer patients and their family members experienced physical, social and psychological benefits from HPN treatment.


11. Kelly L, White S, Stone PC: The B12/CRP index as a simple prognostic indicator in patients with advanced cancer: a confirmatory study. Ann Oncol; 2007 Aug;18(8):1395-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The B12/CRP index as a simple prognostic indicator in patients with advanced cancer: a confirmatory study.
  • BACKGROUND: The vitamin B(12)/C-reactive protein Index (BCI) has been proposed as a prognostic indicator in patients with advanced cancer.
  • PATIENTS AND METHODS: Patients with advanced cancer provided a blood specimen for analysis.
  • CONCLUSIONS: An elevated BCI (>40,000) predicts poor survival in patients with advanced cancer.

  • Hazardous Substances Data Bank. CYANOCOBALAMIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17513884.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 9007-41-4 / C-Reactive Protein; P6YC3EG204 / Vitamin B 12
  •  go-up   go-down


12. Okamoto Y, Tsuneto S, Matsuda Y, Inoue T, Tanimukai H, Tazumi K, Ono Y, Kurokawa N, Uejima E: A retrospective chart review of the antiemetic effectiveness of risperidone in refractory opioid-induced nausea and vomiting in advanced cancer patients. J Pain Symptom Manage; 2007 Aug;34(2):217-22
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A retrospective chart review of the antiemetic effectiveness of risperidone in refractory opioid-induced nausea and vomiting in advanced cancer patients.
  • Nausea and vomiting are distressing symptoms in advanced cancer patients.
  • Among the causes is opioid therapy, the mainstay of cancer pain management.
  • When nausea or other opioid side effects occur, it may hamper pain management and undermine the quality of life of cancer patients.
  • We conducted a retrospective chart review to examine whether risperidone is useful for opioid-induced nausea and vomiting in advanced cancer patients (n=20).
  • This observation suggests that risperidone can be an effective antiemetic drug in the treatment of refractory opioid-induced nausea and vomiting in advanced cancer patients.

  • Genetic Alliance. consumer health - Nausea.
  • Genetic Alliance. consumer health - Vomiting.
  • MedlinePlus Health Information. consumer health - Nausea and Vomiting.
  • Hazardous Substances Data Bank. RISPERIDONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17544249.001).
  • [ISSN] 0885-3924
  • [Journal-full-title] Journal of pain and symptom management
  • [ISO-abbreviation] J Pain Symptom Manage
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Analgesics, Opioid; 0 / Dopamine Antagonists; L6UH7ZF8HC / Risperidone
  •  go-up   go-down


13. Zhang S, Xu G, Liu C, Xiao S, Sun Y, Su X, Cai Y, Li D, Xu B: Clinical study of recombinant adenovirus-p53 (Adp53) combined with hyperthermia in advanced cancer (a report of 15 cases). Int J Hyperthermia; 2005 Nov;21(7):631-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical study of recombinant adenovirus-p53 (Adp53) combined with hyperthermia in advanced cancer (a report of 15 cases).
  • The study was to evaluate the efficacy of the Adp53 combined with hyperthermia on advanced cancer.
  • Fifteen patients with advanced cancer were enrolled in this clinical trial.
  • In conclusion, Adp53 combined with hyperthermia was safe and effective in patients with advanced cancer and p53 gene therapy was potential to thermosensitize in advanced cancer.
  • [MeSH-minor] Adenoviruses, Human / genetics. Adolescent. Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Genes, p53. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / therapy

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16304714.001).
  • [ISSN] 0265-6736
  • [Journal-full-title] International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  • [ISO-abbreviation] Int J Hyperthermia
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Recombinant Proteins; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


14. Mercadante S, Villari P, Ferrera P, David F, Intravaia G: High-dose furosemide and small-volume hypertonic saline solution infusion for the treatment of leg edema in advanced cancer patients. J Pain Symptom Manage; 2009 Mar;37(3):419-23
Hazardous Substances Data Bank. FUROSEMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose furosemide and small-volume hypertonic saline solution infusion for the treatment of leg edema in advanced cancer patients.
  • Peripheral edema is a common feature in populations with advanced cancer, although it is seldom recognized.
  • The aim of this prospective study was to evaluate the efficacy and tolerability of high-dose furosemide and small-volume hypertonic saline solution infusion in reducing leg edema in patients with advanced cancer treated unsuccessfully with diuretics.
  • To be eligible to enter the trial, advanced cancer patients had to have diffuse bilateral leg edema unresponsive to common doses of diuretics.
  • These observations suggest that high-dose furosemide and small-volume saline may be an effective strategy for the treatment of peripheral edema in patients with advanced cancer.

  • Genetic Alliance. consumer health - Edema.
  • MedlinePlus Health Information. consumer health - Edema.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18790601.001).
  • [ISSN] 1873-6513
  • [Journal-full-title] Journal of pain and symptom management
  • [ISO-abbreviation] J Pain Symptom Manage
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Diuretics; 0 / Saline Solution, Hypertonic; 7LXU5N7ZO5 / Furosemide
  •  go-up   go-down


15. Delgado-Guay MO, Yennurajalingam S, Bruera E: Delirium with severe symptom expression related to hypercalcemia in a patient with advanced cancer: an interdisciplinary approach to treatment. J Pain Symptom Manage; 2008 Oct;36(4):442-9
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Delirium with severe symptom expression related to hypercalcemia in a patient with advanced cancer: an interdisciplinary approach to treatment.
  • Delirium is considered to be multifactorial, especially in elderly patients and those with advanced cancer, and can cause significant distress.
  • Hypercalcemia is one of the reversible metabolic causes of delirium in patients with advanced cancer.

  • MedlinePlus Health Information. consumer health - Delirium.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18440772.001).
  • [ISSN] 1873-6513
  • [Journal-full-title] Journal of pain and symptom management
  • [ISO-abbreviation] J Pain Symptom Manage
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Hersh E, Weber J, Powderly J, Pavlik A, Nichol G, Yellin M, Cranmer L, Urba W, O'Day S: Long-term survival of patients (pts) with advanced melanoma treated with ipilimumab with or without dacarbazine. J Clin Oncol; 2009 May 20;27(15_suppl):9038

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival of patients (pts) with advanced melanoma treated with ipilimumab with or without dacarbazine.
  • Here, we report updated survival of pts with advanced melanoma treated with ipilimumab in 2 completed studies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962118.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Agarwala AK, Hanna N, McCollum A, Bechar N, DiMaio M, Yu M, Tong Y, Becerra CR, Choy H: Preoperative cetuximab and radiation (XRT) for patients (pts) with surgically resectable esophageal and gastroesophageal junction (GEJ) carcinomas: A pilot study from the Hoosier Oncology Group and the University of Texas Southwestern. J Clin Oncol; 2009 May 20;27(15_suppl):4557

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cetuximab, when combined with XRT is effective treatment for locally advanced cancers of the head and neck.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963028.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Yamouni M, Benhadji KA, Beldjilali Y, Lahfa I, Khellafi H, Abdelaoui A, Djellali L, Bouzid K: Phase II trial of combination docetaxel and cisplatin in patients with locally advanced nasopharyngeal carcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):6044

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of combination docetaxel and cisplatin in patients with locally advanced nasopharyngeal carcinoma.
  • : 6044 Background: The standard treatment of locally advanced nasopharyngeal carcinoma is cisplatin-based chemotherapy followed by locoregional radiotherapy.
  • METHODS: Previously untreated patients (pts) with histologically diagnosed locally advanced nasopharyngeal carcinoma (stages IVA and IVB, TNM/UICC 1997) received D 75 mg/m<sup>2</sup> and C 75 mg/m<sup>2</sup> both on day 1, with cycles repeated every 21 days.
  • CONCLUSIONS: DC chemotherapy followed by radiation therapy is an effective regimen for the treatment of advanced UCNT and has an acceptable safety profile.
  • These data need to be compared with concurrent chemoradiotherapy to assess the best strategy for the management of advanced UCNT.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961920.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Seo H, Sung H, Choi I, Oh S, Seo J, Shin S, Kim Y, Park K, Kim J: Prognostic significance of serum vascular endothelial growth factor per platelet count in gastric cancer patients. J Clin Oncol; 2009 May 20;27(15_suppl):e22031

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of serum vascular endothelial growth factor per platelet count in gastric cancer patients.
  • : e22031 Background: Recent studies have shown that VEGF expression not in tissues but in serum sample is correlated with tumor vascularity, and high serum VEGF levels could predict poor prognosis in cancer patients.
  • However there are limited data regarding the clinical and prognostic significance of serum VEGF levels per platelet count in advanced gastric cancer.
  • In this study, we conducted a study to evaluate the prognostic implication of serum VEGF per platelet count in patients with advanced gastric cancer.
  • METHODS: 111 patients with histologically confirmed gastric cancer, 10 patients with early gastric cancer were included and control serum samples were acquired from 10 healthy volunteers.
  • Survival curves were calculated using the Kaplan-Meier method and survival comparisons were made by the log rank test in metastatic gastric cancer.
  • CONCLUSIONS: This study demonstrated that serum VEGF per platelet count are correlated with poor overall survival and progression free survival in patients with advanced gastric cancer.
  • Therefore measurement of serum VEGF per platelet might be useful markers for predicting disease progression and prognosis of advanced gastric cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963147.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Schmidt K, Monahan P, Tong Y, Rawl S, Rand K, Cripe LD: Coping styles and psychological outcomes in men with advanced cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e20521

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Coping styles and psychological outcomes in men with advanced cancer.
  • : e20521 Background: The psychological outcomes of men with advanced cancer may vary based upon their appraisal and response to the threat of cancer.
  • Coping styles in other illnesses are influenced by gender and stage of disease, but little is known specifically about men with advanced cancer.
  • METHODS: We recruited 81 men with advanced cancer to complete surveys assessing coping (Mini-MAC), post-traumatic growth (PTGI), and psychological outcomes (Hospital Anxiety and Depression Scale).
  • CONCLUSIONS: As expected men with advanced cancer report anxiety and depression.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961013.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Sherman DW, Norman R, McSherry CB: A comparison of death anxiety and quality of life of patients with advanced cancer or AIDS and their family caregivers. J Assoc Nurses AIDS Care; 2010 Mar-Apr;21(2):99-112
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A comparison of death anxiety and quality of life of patients with advanced cancer or AIDS and their family caregivers.
  • Based on a sample of 101 patients (63 patients with AIDS and 38 with advanced cancer) and 79 family caregivers (43 AIDS patients' caregivers and 36 cancer patients' caregivers), this study examined the death anxiety of patients with advanced cancer and patients with AIDS and that of their family caregivers and the relationship of death anxiety and quality of life.
  • The results indicated that AIDS patients expressed greater death anxiety than cancer patients, but death anxiety was not different among family caregivers.
  • Both AIDS and cancer patients experienced greater death anxiety than their caregivers.


22. Awada AH Sr, Dumez H, Wolter P, Hendlisz A, Besse-Hammer T, Piccart M, Uttenreuther-Fischer M, Stopfer P, Taton M, Schöffski P: A phase I dose finding study of the 3-day administration of BIBW 2992, an irreversible dual EGFR/HER-2 inhibitor, in combination with three-weekly docetaxel in patients with advanced solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):3556

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I dose finding study of the 3-day administration of BIBW 2992, an irreversible dual EGFR/HER-2 inhibitor, in combination with three-weekly docetaxel in patients with advanced solid tumors.
  • METHODS: Patients (pts) had advanced solid malignancies and received docetaxel 75 mg/m<sup>2</sup> i.v. on Day 1 and oral BIBW 2992 once daily on Days 2-4, in 3-week cycles.
  • Four pts (breast cancer [2], thymoma [1], oesophageal carcinoma [1]) had a PR.
  • One breast cancer pt had a confirmed CR.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961365.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Strasser F, Binswanger J, Cerny T, Kesselring A: Fighting a losing battle: eating-related distress of men with advanced cancer and their female partners. A mixed-methods study. Palliat Med; 2007 Mar;21(2):129-37
MedlinePlus Health Information. consumer health - Stress.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fighting a losing battle: eating-related distress of men with advanced cancer and their female partners. A mixed-methods study.
  • BACKGROUND: Anorexia/cachexia is a frequent complication of advanced cancer with poorly understood psychosocial impact or eating-related distress (ERD) on both patients and family members.
  • To assist palliative care practitioners manage this important psychosocial aspect of care, we aimed to discover and describe elements of ERD, focusing on male patients with advanced cancer and their female partners.
  • CONCLUSION: Anorexia/cachexia of male cancer patients affects the cooking at home, a couple's daily eating routines, and their spousal relationship.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17344261.001).
  • [ISSN] 0269-2163
  • [Journal-full-title] Palliative medicine
  • [ISO-abbreviation] Palliat Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


24. Zhou C, Zhou S, Zhang L: RRM1 and BRCA1 mRNA expression levels and clinical outcome of advanced NSCLC patients treated with cisplatin-based chemotherapy. J Clin Oncol; 2009 May 20;27(15_suppl):8097

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] RRM1 and BRCA1 mRNA expression levels and clinical outcome of advanced NSCLC patients treated with cisplatin-based chemotherapy.
  • : 8097 Background: Platinum-based chemotherapy is the standard treatment for advanced NSCLC patients.
  • CONCLUSIONS: RRM1 and BRCA1 mRNA expression levels in non-small cell lung cancer are associated with clinical outcome to cisplatin-based chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962675.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Sinha D, Bahadur AK, Singh K, Rathi AK: Comparison of neoadjuvant paclitaxel and carboplatin with neoadjuvant letrozole in postmenopausal patients with receptor-positive locally advanced breast cancer (LABC). J Clin Oncol; 2009 May 20;27(15_suppl):608

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of neoadjuvant paclitaxel and carboplatin with neoadjuvant letrozole in postmenopausal patients with receptor-positive locally advanced breast cancer (LABC).
  • Paclitaxel was the first taxane to show activity in breast cancer.
  • The aromatase inhibitors are now the treatment of choice in neoadjuvant setting for elderly patients with estrogen receptor-positive breast cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961471.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Cherny NI: Evaluation and management of treatment-related diarrhea in patients with advanced cancer: a review. J Pain Symptom Manage; 2008 Oct;36(4):413-23
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation and management of treatment-related diarrhea in patients with advanced cancer: a review.
  • Diarrhea is a common and significant problem among patients with advanced cancer.
  • The causes of diarrhea among patients with advanced cancer are diverse and some causes of diarrhea require specific therapies.
  • Palliative care clinicians, particularly those dealing with patients receiving ongoing disease-modifying therapies, must be familiar with the common causes of diarrhea among cancer patients and the strategies to evaluate and manage these common and distressing symptoms.

  • Genetic Alliance. consumer health - Diarrhea.
  • MedlinePlus Health Information. consumer health - Diarrhea.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18411014.001).
  • [ISSN] 1873-6513
  • [Journal-full-title] Journal of pain and symptom management
  • [ISO-abbreviation] J Pain Symptom Manage
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antidiarrheals
  • [Number-of-references] 80
  •  go-up   go-down


27. Okamura M, Akizuki N, Nakano T, Shimizu K, Ito T, Akechi T, Uchitomi Y: Clinical experience of the use of a pharmacological treatment algorithm for major depressive disorder in patients with advanced cancer. Psychooncology; 2008 Feb;17(2):154-60
Hazardous Substances Data Bank. AMITRIPTYLINE HYDROCHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical experience of the use of a pharmacological treatment algorithm for major depressive disorder in patients with advanced cancer.
  • The objective of this study was to describe the applicability and the dropout of the pharmacological treatment algorithm for major depressive disorder in patients with advanced cancer.
  • Psychiatrists treated major depressive disorder in advanced cancer patients on the basis of the algorithm.
  • [MeSH-minor] Adult. Aged. Alprazolam / therapeutic use. Amitriptyline / therapeutic use. Anxiety Disorders / epidemiology. Anxiety Disorders / prevention & control. Anxiety Disorders / psychology. Central Nervous System Stimulants / therapeutic use. Clomipramine / therapeutic use. Disease Progression. Drug Therapy, Combination. Female. Humans. Male. Methylphenidate / therapeutic use. Middle Aged. Neoplasm Staging. Prognosis. Severity of Illness Index

  • Genetic Alliance. consumer health - Major depressive disorder.
  • MedlinePlus Health Information. consumer health - Antidepressants.
  • Hazardous Substances Data Bank. METHYLPHENIDATE .
  • Hazardous Substances Data Bank. ALPRAZOLAM .
  • Hazardous Substances Data Bank. Clomipramine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17461435.001).
  • [ISSN] 1057-9249
  • [Journal-full-title] Psycho-oncology
  • [ISO-abbreviation] Psychooncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antidepressive Agents; 0 / Central Nervous System Stimulants; 12794-10-4 / Benzodiazepines; 1806D8D52K / Amitriptyline; 207ZZ9QZ49 / Methylphenidate; NUV44L116D / Clomipramine; YU55MQ3IZY / Alprazolam
  •  go-up   go-down


28. Helft PR, Terry C, Chamness AR, Uhrich MM: Oncology nurses' views of oncologists' prognosis-related communication (PRC). J Clin Oncol; 2009 May 20;27(15_suppl):6602

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 6602 Background: PRC is critical to care, treatment, and decision-making for advanced cancer patients (ACP).
  • METHODS: Mail survey of a random sample of Oncology Nursing Society members with at least one year of experience working with cancer patients (pts).
  • RESULTS: Respondent demographics: median age 49.2, 96.6% female, 88.5% Caucasian, median years (yrs) as an RN 18, median yrs working with cancer patients 12, 69.1% had a BSN or ASN, 34.1% inpt RNs, 38.6% outpt RNs.
  • 25.1% of RNs felt that MDs rarely or never kept them informed about their PRC with pts (frequency positively associated with yrs as an RN, yrs working with cancer pts, education level).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961728.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Sanchez A, Provencio M, Artal A, Constenla M, Garcia-Gomez R, Viñolas N, Domine M, Perez FJ, Gayo J: Cisplatin (CDDP) plus oral vinorelbine (NVBO) as first-line treatment for advanced non-small cell lung cancer (NSCLC): Prospective analysis to improve the patient's convenience on day 8 NVBO administration. J Clin Oncol; 2009 May 20;27(15_suppl):e19096

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cisplatin (CDDP) plus oral vinorelbine (NVBO) as first-line treatment for advanced non-small cell lung cancer (NSCLC): Prospective analysis to improve the patient's convenience on day 8 NVBO administration.
  • The results of a previous study with 180 p treated with IV vinorelbine plus CDDP as first-line treatment for advanced NSCLC could lead to consider not performing a blood count prior to day 8 vinorelbine administration for patients aged 70 years (y) or less who presented a good haematological tolerability profile during previous cycles (cy) in order to improve treatment convenience.
  • CONCLUSIONS: The findings of this study could lead to consider not performing a blood count prior to day 8 NVBO administration for patients aged 70 y or less who presented a good haematological tolerability profile during previous cycles in first-line treatment for advanced NSCLC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962248.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Besse B, Almokadem S, Planchard D, Chico I, Tsao CL, Ringeisen F, Soria J, Belani CP: Safety and early efficacy results from a phase I study of volociximab (V) in combination with carboplatin (C) and paclitaxel (P) in patients (pts) with advanced non small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):e13513

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety and early efficacy results from a phase I study of volociximab (V) in combination with carboplatin (C) and paclitaxel (P) in patients (pts) with advanced non small cell lung cancer (NSCLC).
  • This is the first clinical study of voloxicimab in patients with advanced NSCLC.
  • CONCLUSIONS: The highest dose of V tested (30 mg/kg q3w) in combination with CP appears well tolerated and the regimen has promising clinical activity in advanced NSCLC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961304.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Tsuburaya A, Narahara H, Imamura H, Hatake K, Imamoto H, Esaki T, Kato M, Furukawa H, Hamada C, Sakata Y, GC0301/TOP-002 Study Group: Updated result on the 2.5-year follow-up of GC0301/TOP-002: Randomized phase III study of irinotecan plus S-1 (IRI-S) versus S-1 alone as first-line treatment for advanced gastric cancer (AGC). J Clin Oncol; 2009 May 20;27(15_suppl):4544

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Updated result on the 2.5-year follow-up of GC0301/TOP-002: Randomized phase III study of irinotecan plus S-1 (IRI-S) versus S-1 alone as first-line treatment for advanced gastric cancer (AGC).
  • We need more considering predictive factors, because the gastric cancer is heterogeneous adenocarcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963013.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Correa-Velez I, Clavarino A, Eastwood H: Surviving, relieving, repairing, and boosting up: reasons for using complementary/alternative medicine among patients with advanced cancer: a thematic analysis. J Palliat Med; 2005 Oct;8(5):953-61
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surviving, relieving, repairing, and boosting up: reasons for using complementary/alternative medicine among patients with advanced cancer: a thematic analysis.
  • BACKGROUND: Patients with advanced cancer commonly use complementary and alternative medicine (CAM), however, little research has been undertaken on their reasons for doing so.
  • OBJECTIVES: This study sought to identify in detail the reasons for using CAM among patients with advanced cancer.
  • SETTING/SUBJECTS: Interviews conducted with 39 patients who were participating in a longitudinal study exploring the levels of palliative care received by patients with cancer in Brisbane, Australia.
  • All participants were receiving or had received conventional cancer treatments.
  • RESULTS: Most participants self-treated with CAM and perceived CAM modalities as complementary rather than alternative to conventional cancer treatments.
  • Within this context, this group of people used CAM to prolong their survival, palliate their symptoms or alleviate the side effects of conventional cancer treatments, detoxify their bodies, boost immunity and enhance their overall quality of life.
  • CONCLUSION: When facing an incurable life-threatening illness such as advanced cancer, the decision to use CAM is a pragmatic one.
  • Screening for physical, emotional, and spiritual discomfort associated not only with the disease but with some of the cancer treatments needs to be given a prominent place in the clinical encounter.
  • Patients with cancer want to know more about how to maintain or improve their quality of life during and after surgery, radiation, or chemotherapy.


33. Stockler MR, O'Connell R, Nowak AK, Goldstein D, Turner J, Wilcken NR, Wyld D, Abdi EA, Glasgow A, Beale PJ, Jefford M, Dhillon H, Heritier S, Carter C, Hickie IB, Simes RJ, Zoloft's Effects on Symptoms and survival Time Trial Group: Effect of sertraline on symptoms and survival in patients with advanced cancer, but without major depression: a placebo-controlled double-blind randomised trial. Lancet Oncol; 2007 Jul;8(7):603-12
Hazardous Substances Data Bank. SERTRALINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of sertraline on symptoms and survival in patients with advanced cancer, but without major depression: a placebo-controlled double-blind randomised trial.
  • BACKGROUND: Depression, anxiety, fatigue, and impaired wellbeing are common, important, and closely related in advanced cancer.
  • We aimed to identify the effects of an established antidepressant on these symptoms and survival in patients with advanced cancer who did not have major depression as assessed by clinicians.
  • METHODS: Between July, 2001, and February, 2006, 189 patients with advanced cancer were randomly assigned sertraline 50 mg (n=95), or placebo (n=94), once per day.
  • The primary outcome was depression as assessed by the Centre for Epidemiologic Studies Depression scale (CES-D); the main secondary outcomes were: anxiety as assessed by Hospital Anxiety and Depression Scales (HADS-A); overall quality of life and fatigue as assessed by Functional Assessment of Cancer Therapy General and Fatigue scales (FACT-G and FACT-F, respectively); and clinicians' ratings of quality of life by use of Spizter's Quality of Life Index (SQLI).
  • INTERPRETATION: Sertraline did not improve symptoms, wellbeing, or survival in patients with advanced cancer who do not have major depression, and should be reserved for those with a proven indication.

  • Genetic Alliance. consumer health - Depression.
  • Genetic Alliance. consumer health - Major depressive disorder.
  • MedlinePlus Health Information. consumer health - Antidepressants.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Lancet Oncol. 2007 Jul;8(7):567-8 [17613418.001]
  • [ErratumIn] Lancet Oncol. 2007 Jul 8;8(7):574
  • (PMID = 17548243.001).
  • [ISSN] 1470-2045
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Databank-accession-numbers] ISRCTN/ ISRCTN72466475
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antidepressive Agents; 0 / Placebos; QUC7NX6WMB / Sertraline
  •  go-up   go-down


34. Underhill C, Millward M, Lobb S, McBurnie J, Meech S, Gomez-Navarro J, Readett D, Bulanhagui CA: Phase I dose escalation trial of tremelimumab (CP-675,206) administered in combination with PF-3512676 in patients with melanoma or other advanced cancers. J Clin Oncol; 2009 May 20;27(15_suppl):3046

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I dose escalation trial of tremelimumab (CP-675,206) administered in combination with PF-3512676 in patients with melanoma or other advanced cancers.
  • : 3046 Background: Tremelimumab, a fully human monoclonal antibody specific for cytotoxic T-lymphocyte antigen 4 (CTLA4), and PF-3512676, an oligodeoxynucleotide toll-like receptor 9 agonist, are both novel, targeted immune modulators that can elicit durable antitumor responses in patients with advanced cancer.
  • METHODS: Eligibility criteria included advanced melanoma or other advanced cancer, ECOG performance status of 0 or 1, and no history of autoimmune disease.
  • CONCLUSIONS: At dose levels tested to date, the combination of tremelimumab and PF-3512676 has been tolerable and showed evidence of antitumor activity in patients with advanced melanoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961977.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Sherman DW, Ye XY, Beyer McSherry C, Parkas V, Calabrese M, Gatto M: Symptom assessment of patients with advanced cancer and AIDS and their family caregivers: the results of a quality-of-life pilot study. Am J Hosp Palliat Care; 2007 Oct-Nov;24(5):350-65
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Symptom assessment of patients with advanced cancer and AIDS and their family caregivers: the results of a quality-of-life pilot study.
  • This longitudinal pilot study examined differences in demographic characteristics of 101 patients with advanced illness (cancer, AIDS) and 81 Family caregivers, evaluated the reliability of the Memorial Symptom Assessment Scale for these patients and their family caregivers; obtained preliminary data regarding similarities or differences in the symptom experience oF these patients and their family caregivers and changes in symptoms over time; and identified demographic variables that may be potential covariates related to the symptom experience.
  • All demographic variables were significantly different for patients with advanced cancer and AIDS, and their symptom experience is similar only with regard to psychologic symptoms; however, based on the Memorial Symptom Assessment Scale, cancer and AIDS patients and their family caregivers have similar symptom experiences, indicating the need for palliative care for both patients and family.


36. Strasser F, Müller-Käser I, Dietrich D: Evaluating cognitive, emotional, and physical fatigue domains in daily practice by single-item questions in patients with advanced cancer: a cross-sectional pragmatic study. J Pain Symptom Manage; 2009 Oct;38(4):505-14
MedlinePlus Health Information. consumer health - Fatigue.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluating cognitive, emotional, and physical fatigue domains in daily practice by single-item questions in patients with advanced cancer: a cross-sectional pragmatic study.
  • To assess cancer-related fatigue (CRF), multidimensional questionnaires are required.
  • Sixty-one fatigued patients with advanced cancer completed SIF assessments (visual analog scales for global fatigue and for fatigue in the cognitive, emotional, and physical domains, respectively), and the Brief Fatigue Inventory (BFI), the Fatigue Assessment Questionnaire (FAQ), the Hospital Anxiety and Depression Scale (HADS), and the European Organization for Research and Treatment of Cancer (EORTC) Quality-of-Life-C30 (QLQ-C30).
  • These data suggest that three simple SIF questions permit rapid assessment of the physical and cognitive and probably the emotional domains of CRF in patients with advanced cancer.

  • MedlinePlus Health Information. consumer health - Anxiety.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19822275.001).
  • [ISSN] 1873-6513
  • [Journal-full-title] Journal of pain and symptom management
  • [ISO-abbreviation] J Pain Symptom Manage
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Maltoni M, Caraceni A, Brunelli C, Broeckaert B, Christakis N, Eychmueller S, Glare P, Nabal M, Viganò A, Larkin P, De Conno F, Hanks G, Kaasa S, Steering Committee of the European Association for Palliative Care: Prognostic factors in advanced cancer patients: evidence-based clinical recommendations--a study by the Steering Committee of the European Association for Palliative Care. J Clin Oncol; 2005 Sep 1;23(25):6240-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors in advanced cancer patients: evidence-based clinical recommendations--a study by the Steering Committee of the European Association for Palliative Care.
  • PURPOSE: To offer evidence-based clinical recommendations concerning prognosis in advanced cancer patients.
  • Only studies on patients with advanced cancer and survival < or = 90 days were included.
  • Recommendations on the use of other prognostic factors, such as performance status, symptoms associated with cancer anorexia-cachexia syndrome (weight loss, anorexia, dysphagia, and xerostomia), dyspnea, delirium, and some biologic factors (leukocytosis, lymphocytopenia, and C-reactive protein), reached level B.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16135490.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers
  • [Number-of-references] 80
  •  go-up   go-down


38. Lee MS, Yang SH, Lee KK, Moon SR: Effects of Qi therapy (external Qigong) on symptoms of advanced cancer: a single case study. Eur J Cancer Care (Engl); 2005 Dec;14(5):457-62
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of Qi therapy (external Qigong) on symptoms of advanced cancer: a single case study.
  • The aim of this study was to examine the effectiveness of Qi therapy (external Qigong) in the management of symptoms of advanced cancer in a man.
  • We used a single case study design to evaluate the effectiveness of Qi therapy (external Qigong) in a 35-year-old man with advanced cancer (Stage IV) involving metastases in the stomach, lung and bone (Karnofsky performance scale: KPS, 40: requires special care and assistance, disabled).
  • A visual analogue scale (VAS) was used to assess the patient's self-reported symptoms of cancer over the intervention and follow-up periods.

  • MedlinePlus Health Information. consumer health - Fatigue.
  • MedlinePlus Health Information. consumer health - Insomnia.
  • MedlinePlus Health Information. consumer health - Nausea and Vomiting.
  • MedlinePlus Health Information. consumer health - Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16274468.001).
  • [ISSN] 0961-5423
  • [Journal-full-title] European journal of cancer care
  • [ISO-abbreviation] Eur J Cancer Care (Engl)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


39. Drevs J, Medinger M, Mross K, Fuxius S, Hennig J, Buechert M, Thomas A, Unger C, Chen BL, Lebwohl D, Laurent D: A phase IA, open-label, dose-escalating study of PTK787/ZK 222584 administered orally on a continuous dosing schedule in patients with advanced cancer. Anticancer Res; 2010 Jun;30(6):2335-9
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase IA, open-label, dose-escalating study of PTK787/ZK 222584 administered orally on a continuous dosing schedule in patients with advanced cancer.
  • Seventy-one patients with advanced cancer were enrolled to receive once daily dosing.
  • CONCLUSION: An MTD was not reached in this study but, based on these data and findings from other studies, 1200 mg was found to be the optimum dose of PTK/ZK for patients with advanced cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20651389.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Phthalazines; 0 / Protein Kinase Inhibitors; 0 / Pyridines; 0 / Vascular Endothelial Growth Factor A; 103107-01-3 / Fibroblast Growth Factor 2; 5DX9U76296 / vatalanib
  •  go-up   go-down


40. Yennurajalingam S, Dev R, Walker PW, Reddy SK, Bruera E: Challenges associated with spinal opioid therapy for pain in patients with advanced cancer: a report of three cases. J Pain Symptom Manage; 2010 May;39(5):930-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Challenges associated with spinal opioid therapy for pain in patients with advanced cancer: a report of three cases.
  • Intraspinal opioid therapy has been increasingly used for the management of cancer pain refractory to traditional treatment.
  • However, this approach may present challenges in patients with advanced cancer.
  • Three cases are presented that highlight the challenges associated with using neuraxial analgesia to manage cancer pain that was felt to be "refractory" to conventional treatment.

  • MedlinePlus Health Information. consumer health - Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20471553.001).
  • [ISSN] 1873-6513
  • [Journal-full-title] Journal of pain and symptom management
  • [ISO-abbreviation] J Pain Symptom Manage
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Analgesics, Opioid
  •  go-up   go-down


41. Ishikawa H, Saeki T, Otani T, Suzuki T, Shimozuma K, Nishino H, Fukuda S, Morimoto K: Aged garlic extract prevents a decline of NK cell number and activity in patients with advanced cancer. J Nutr; 2006 Mar;136(3 Suppl):816S-820S
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aged garlic extract prevents a decline of NK cell number and activity in patients with advanced cancer.
  • Advanced-cancer patients decline in immune functions and quality of life (QOL).
  • The study's subjects were patients with inoperable colorectal, liver, or pancreatic cancer.
  • The primary endpoint was a QOL questionnaire based on the Functional Assessment of Cancer Therapy (FACT).
  • They consisted of 42 patients with liver cancer (84%), 7 patients with pancreatic cancer (14%), and 1 patient with colon cancer (2%).
  • The study showed that administering AGE to patients with advanced cancer of the digestive system improved NK cell activity, but caused no improvement in QOL.

  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16484572.001).
  • [ISSN] 0022-3166
  • [Journal-full-title] The Journal of nutrition
  • [ISO-abbreviation] J. Nutr.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Placebos; 0 / Plant Extracts
  •  go-up   go-down


42. Porzio G, Aielli F, Verna L, Aloisi P, Galletti B, Ficorella C: Gabapentin in the treatment of hiccups in patients with advanced cancer: a 5-year experience. Clin Neuropharmacol; 2010 Jul;33(4):179-80
Hazardous Substances Data Bank. GABAPENTIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gabapentin in the treatment of hiccups in patients with advanced cancer: a 5-year experience.
  • AIM: To evaluate safety and efficacy of gabapentin in the treatment of severe chronic hiccups in patients with advanced cancer.
  • CONCLUSION: The results of the study allow suggesting gabapentin at least as a promising drug in the treatment of severe chronic hiccups in advanced cancer patients.

  • MedlinePlus Health Information. consumer health - Hiccups.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20414106.001).
  • [ISSN] 1537-162X
  • [Journal-full-title] Clinical neuropharmacology
  • [ISO-abbreviation] Clin Neuropharmacol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Amines; 0 / Calcium Channel Blockers; 0 / Cyclohexanecarboxylic Acids; 56-12-2 / gamma-Aminobutyric Acid; 6CW7F3G59X / gabapentin
  •  go-up   go-down


43. Wu JC, Hakama M, Anttila A, Yen AM, Malila N, Sarkeala T, Auvinen A, Chiu SY, Chen HH: Estimation of natural history parameters of breast cancer based on non-randomized organized screening data: subsidiary analysis of effects of inter-screening interval, sensitivity, and attendance rate on reduction of advanced cancer. Breast Cancer Res Treat; 2010 Jul;122(2):553-66
MedlinePlus Health Information. consumer health - Mammography.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Estimation of natural history parameters of breast cancer based on non-randomized organized screening data: subsidiary analysis of effects of inter-screening interval, sensitivity, and attendance rate on reduction of advanced cancer.
  • Estimating the natural history parameters of breast cancer not only elucidates the disease progression but also make contributions to assessing the impact of inter-screening interval, sensitivity, and attendance rate on reducing advanced breast cancer.
  • Computer simulation was implemented to examine the effect of inter-screening interval, sensitivity, and attendance rate on reducing advanced breast cancers.
  • In three-state model, the MST was 2.02 years, and the sensitivity for detecting preclinical breast cancer was 84.83%.
  • Annual, biennial, and triennial screening programs can reduce 53, 37, and 28% of advanced cancer.
  • We demonstrated how to estimate the natural history parameters using a service screening program and applied these parameters to assess the impact of inter-screening interval, sensitivity, and attendance rate on reducing advanced cancer.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20054645.001).
  • [ISSN] 1573-7217
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


44. Chvetzoff G, Perol D, Devaux Y, Lancry L, Rebattu P, Magnet M, Dubost E, Bertrand M, Garcon C, Thevenet G, Gobet S, Arbiol E, Saltel P: [Prospective study on the quality of care and quality of life in advanced cancer patients treated at home or in hospital: intermediate analysis of the Trapado study]. Bull Cancer; 2006 Feb;93(2):213-21
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prospective study on the quality of care and quality of life in advanced cancer patients treated at home or in hospital: intermediate analysis of the Trapado study].
  • The preferences of advanced cancer patients and the impact of cancer management on relatives remain partly unknown.
  • We present the preliminary results of a prospective study evaluating quality of care (QC), quality of life (QoL) and family impact (FI) in advanced cancer patients treated at home or in hospital, depending on their own choice.

  • MedlinePlus Health Information. consumer health - Home Care Services.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16517418.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


45. O'Hara RE, Hull JG, Lyons KD, Bakitas M, Hegel MT, Li Z, Ahles TA: Impact on caregiver burden of a patient-focused palliative care intervention for patients with advanced cancer. Palliat Support Care; 2010 Dec;8(4):395-404
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact on caregiver burden of a patient-focused palliative care intervention for patients with advanced cancer.
  • OBJECTIVE: Caregivers of patients with advanced cancer experience physical and emotional strain that can raise their own risk for morbidity and mortality.
  • METHOD: Caregivers of patients with advanced cancer from the parent study completed a caregiver burden scale and patients completed quality of life, symptom intensity, and depressed mood measures.

  • MedlinePlus Health Information. consumer health - Cancer--Living with Cancer.
  • MedlinePlus Health Information. consumer health - Caregivers.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • MedlinePlus Health Information. consumer health - Stress.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] JAMA. 1999 Dec 15;282(23):2215-9 [10605972.001]
  • [Cites] JAMA. 2009 Aug 19;302(7):741-9 [19690306.001]
  • [Cites] Psychol Aging. 2000 Jun;15(2):259-71 [10879581.001]
  • [Cites] Am J Nurs. 2000 Dec;100(12):26-31; quiz 32 [11202781.001]
  • [Cites] Oncol Nurs Forum. 2001 Aug;28(7):1149-57 [11517848.001]
  • [Cites] J Pain Symptom Manage. 2001 Sep;22(3):752-8 [11532588.001]
  • [Cites] Health Psychol. 2001 Nov;20(6):452-7 [11714188.001]
  • [Cites] Gerontologist. 2002 Jun;42(3):356-72 [12040138.001]
  • [Cites] Soc Sci Med. 2003 Jan;56(1):95-109 [12435554.001]
  • [Cites] Palliat Med. 2003 Jan;17(1):63-74 [12597468.001]
  • [Cites] J Gerontol B Psychol Sci Soc Sci. 2003 Mar;58(2):P112-28 [12646594.001]
  • [Cites] Psychol Aging. 2003 Jun;18(2):250-67 [12825775.001]
  • [Cites] Support Care Cancer. 2003 Oct;11(10):638-43 [12905058.001]
  • [Cites] Palliat Med. 2004 Mar;18(2):108-20 [15046407.001]
  • [Cites] J Palliat Care. 1991 Summer;7(2):6-9 [1714502.001]
  • [Cites] Soc Sci Med. 1995 Feb;40(4):517-28 [7725125.001]
  • [Cites] Cancer Treat Rev. 1996 Jan;22 Suppl A:3-12 [8625346.001]
  • [Cites] J Pain Symptom Manage. 1997 Mar;13(3):138-47 [9114632.001]
  • [Cites] Nurs Res. 1998 Jan-Feb;47(1):2-10 [9478178.001]
  • [Cites] Psychooncology. 1998 Jan-Feb;7(1):3-13 [9516646.001]
  • [Cites] Image J Nurs Sch. 1999;31(2):115-20 [10380385.001]
  • [Cites] Oncol Nurs Forum. 2004 Nov;31(6):1105-17 [15547633.001]
  • [Cites] J Pain Symptom Manage. 2005 Aug;30(2):112-22 [16125026.001]
  • [Cites] J Pain Symptom Manage. 2005 Oct;30(4):329-41 [16256897.001]
  • [Cites] Cancer. 2006 Jan 1;106(1):214-22 [16329131.001]
  • [Cites] N Engl J Med. 2006 Feb 16;354(7):719-30 [16481639.001]
  • [Cites] Am J Hosp Palliat Care. 2006 Jun-Jul;23(3):185-91 [17060277.001]
  • [Cites] Arch Intern Med. 2007 Jan 8;167(1):40-6 [17210876.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4829-34 [17947732.001]
  • [Cites] J Pain Symptom Manage. 2007 Nov;34(5):539-46 [17616333.001]
  • [Cites] J Psychosom Res. 2007 Dec;63(6):617-23 [18061752.001]
  • [Cites] Ann Intern Med. 2008 Jan 15;148(2):147-59 [18195339.001]
  • [Cites] Psychol Bull. 2008 Jan;134(1):1-30 [18193993.001]
  • [Cites] Clin J Oncol Nurs. 2008 Jun;12(3):507-16 [18515250.001]
  • [Cites] Am J Public Health. 2008 Nov;98(11):2092-8 [18511733.001]
  • [Cites] J Clin Oncol. 2008 Dec 20;26(36):5890-5 [19029423.001]
  • [Cites] J Pain Symptom Manage. 2009 Jan;37(1):23-32 [18504093.001]
  • [Cites] Palliat Support Care. 2009 Mar;7(1):75-86 [19619377.001]
  • [Cites] Cancer Treat Res. 1999;100:203-16 [10645504.001]
  • (PMID = 20875202.001).
  • [ISSN] 1478-9523
  • [Journal-full-title] Palliative & supportive care
  • [ISO-abbreviation] Palliat Support Care
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA101704; United States / NCI NIH HHS / CA / CA101704-03; United States / NCI NIH HHS / CA / CA101704-02; United States / NCI NIH HHS / CA / P30 CA023108; United States / NCI NIH HHS / CA / R01 CA101704-01; United States / NCI NIH HHS / CA / R01 CA101704-02; United States / NCI NIH HHS / CA / R01 CA101704-03; United States / NCI NIH HHS / CA / CA101704-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS277192; NLM/ PMC3063059
  •  go-up   go-down


46. Homma A, Oridate N, Suzuki F, Taki S, Asano T, Yoshida D, Onimaru R, Nishioka T, Shirato H, Fukuda S: Superselective high-dose cisplatin infusion with concomitant radiotherapy in patients with advanced cancer of the nasal cavity and paranasal sinuses: a single institution experience. Cancer; 2009 Oct 15;115(20):4705-14
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Superselective high-dose cisplatin infusion with concomitant radiotherapy in patients with advanced cancer of the nasal cavity and paranasal sinuses: a single institution experience.
  • BACKGROUND: The current study aimed to evaluate the efficacy of superselective high-dose cisplatin infusion with concomitant radiotherapy (RADPLAT) for previously untreated patients with advanced cancer of the nasal cavity and paranasal sinuses.
  • CONCLUSIONS: Although a single institution experience, the results of the current study suggest that RADPLAT can cure the majority of patients with advanced cancer of the nasal cavity and paranasal sinuses, as well as preserve organs.
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy / adverse effects. Disease Progression. Female. Humans. Infusions, Intra-Arterial. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local. Survival Analysis. Thiosulfates / administration & dosage

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 American Cancer Society.
  • (PMID = 19634162.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Thiosulfates; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


47. Brown ER, Charles KA, Hoare SA, Rye RL, Jodrell DI, Aird RE, Vora R, Prabhakar U, Nakada M, Corringham RE, DeWitte M, Sturgeon C, Propper D, Balkwill FR, Smyth JF: A clinical study assessing the tolerability and biological effects of infliximab, a TNF-alpha inhibitor, in patients with advanced cancer. Ann Oncol; 2008 Jul;19(7):1340-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A clinical study assessing the tolerability and biological effects of infliximab, a TNF-alpha inhibitor, in patients with advanced cancer.
  • Infliximab, an anti-TNF-alpha monoclonal antibody was investigated in this trial of patients with advanced cancer.
  • The primary objectives were to determine the safety profile and biological response of infliximab in a cancer population.
  • Post-treatment samples were measured for changes in plasma and serum TNF-alpha, CCL2, IL-6 and C-reactive protein (CRP).
  • At both doses of infliximab, neutralisation of serum TNF-alpha was observed after 1 h while plasma CCL2, IL-6 and serum CRP were decreased 24 and 48 h following infliximab administration.
  • CONCLUSIONS: Infliximab treatment was safe and well tolerated in patients with advanced cancer.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Infliximab .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18325912.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0501974
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / CCL2 protein, human; 0 / Chemokine CCL2; 0 / Interleukin-6; 0 / Tumor Necrosis Factor-alpha; 9007-41-4 / C-Reactive Protein; B72HH48FLU / Infliximab
  •  go-up   go-down


48. Schoenegg W: Capecitabine (X) in the routine treatment of advanced breast cancer (BC): Results from a large (n = 870) noninterventional study. J Clin Oncol; 2009 May 20;27(15_suppl):e12021

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Capecitabine (X) in the routine treatment of advanced breast cancer (BC): Results from a large (n = 870) noninterventional study.
  • METHODS: Pts with advanced BC pretreated with or ineligible for anthracycline-containing therapy received X.
  • CONCLUSIONS: X, either alone or in combination, is a feasible and effective treatment for advanced BC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964311.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Trinkaus ME, Sayed S, Gakinya S, Hanna W, Moloo Z, Rahim Y: External quality assurance of breast cancer pathologic reporting in Kenya. J Clin Oncol; 2009 May 20;27(15_suppl):e11586

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] External quality assurance of breast cancer pathologic reporting in Kenya.
  • : e11586 Background: Eighty percent of women diagnosed with breast cancer (BC) in East Africa present with advanced disease; current literature suggests a preponderance of triple negative/basal like breast cancer in this subset of African women.
  • The objective of this study is to provide external quality assurance (EQA), quality control, and validation of hormone receptor and Her2 status of breast cancer specimens from Kenya.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964121.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Maximous D, Abdel-Wanis ME, Aboziada MA, El-Sayed MI, Abd-Elsayed AA: Preoperative gemcitabine based chemoradiotherapy in locally advanced nonmetastatic pancreatic adenocarcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):e15677

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative gemcitabine based chemoradiotherapy in locally advanced nonmetastatic pancreatic adenocarcinoma.
  • : e15677 Background: Almost 30% of patients with pancreatic cancer present with locally advanced tumours in absence of distant metastasis.
  • The combination of gemcitabine with concurrent radiation therapy is a promising approach that is being investigated in patients' unresectable pancreatic cancer.
  • AIM OF THE WORK: The efficacy of preoperative gemcitabine based chemo-radiotherapy in increasing the resectability rate for patients locally advanced, non metastatic pancreatic cancer was assessed.
  • CONCLUSIONS: preoperative gemcitabine based chemoradiation might benefit patients with locally advanced non metastatic pancreatic cancer by increasing the resectability without significant acute toxicity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962829.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Moss AH, Lunney JR, Culp S, Auber M, Kurian S, Rogers J, Dower J, Abraham J: Prognostic significance of the "surprise" question in cancer patients. J Clin Oncol; 2009 May 20;27(15_suppl):9588

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of the "surprise" question in cancer patients.
  • : 9588 Background: In patients with advanced cancer, failure to accurately estimate and communicate prognoses can lead to overly aggressive care at the end of life with less attention to important palliative care issues such as pain and symptom management and patients' values and goals for care.
  • It has not been previously tested in cancer patients.
  • The purposes of this study were to determine the feasibility and outcomes of the use of the "surprise" question in a cancer center population.
  • METHODS: Between July and November 2007, oncologists prospectively classified consecutive breast, lung, and colon cancer patients being seen at the Mary Babb Randolph Cancer Center of West Virginia University into "Yes" and "No" groups based on the surprise question.
  • Patients were followed and their status at the end of one year-alive or dead-was determined along with patient demographics, type of cancer, and stage at presentation.
  • The surprise question 'No' response was more predictive of patient death than stage of cancer, cancer type, or age (hazard ratio 7.53, P value <.001).
  • CONCLUSIONS: We conclude that the surprise question is a simple, feasible, and effective tool to identify cancer patients with the worst prognoses who should receive the highest priority for palliative care interventions, particularly advance care planning.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963736.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Miller JJ, Frost MH, Rummans TA, Huschka M, Atherton P, Brown P, Gamble G, Richardson J, Hanson J, Sloan JA, Clark MM: Role of a medical social worker in improving quality of life for patients with advanced cancer with a structured multidisciplinary intervention. J Psychosoc Oncol; 2007;25(4):105-19
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of a medical social worker in improving quality of life for patients with advanced cancer with a structured multidisciplinary intervention.
  • <i> BACKGROUND: </i> Patients with advanced cancer face multiple challenges to their quality of life (QOL).
  • The goal of this study was to investigate the impact of participation in a multidisciplinary intervention, including a social service component, on improving the QOL of patients with advanced cancer undergoing radiation therapy.
  • <i> DESIGN: </i> A total of 115 participants with newly diagnosed advanced stage cancer, who were receiving radiation therapy, were randomly assigned to either participate in an 8-session structured multidisciplinary intervention or to receive standard care.
  • <i> CONCLUSIONS: </i> A social work component within a structured multidisciplinary intervention results in significant advantages in the social domain of QOL, and contributes to clinically meaningful improvements in the overall QOL for patients with advanced cancer undergoing active medical treatment.
  • Numerous studies have documented the financial burdens and social changes that may occur with the diagnosis of cancer.
  • [MeSH-major] Health Services / standards. Interdisciplinary Communication. Neoplasm Staging. Neoplasms. Patient Care Team. Quality of Life / psychology. Social Work

  • MedlinePlus Health Information. consumer health - Cancer--Living with Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18032268.001).
  • [ISSN] 0734-7332
  • [Journal-full-title] Journal of psychosocial oncology
  • [ISO-abbreviation] J Psychosoc Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


53. Currow DC, Plummer JL, Cooney NJ, Gorman D, Glare PA: A randomized, double-blind, multi-site, crossover, placebo-controlled equivalence study of morning versus evening once-daily sustained-release morphine sulfate in people with pain from advanced cancer. J Pain Symptom Manage; 2007 Jul;34(1):17-23
Hazardous Substances Data Bank. MORPHINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized, double-blind, multi-site, crossover, placebo-controlled equivalence study of morning versus evening once-daily sustained-release morphine sulfate in people with pain from advanced cancer.
  • The study recruited 45 people with opioid-responsive pain on stable doses of analgesics and advanced cancer from five regional palliative care programs in Australia.
  • This study suggests that any difference between morning and evening dosing of once-daily sustained-release morphine in people with significant opioid-responsive pain and advanced cancer is small and unlikely to be clinically significant for most people.

  • MedlinePlus Health Information. consumer health - Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17601560.001).
  • [ISSN] 0885-3924
  • [Journal-full-title] Journal of pain and symptom management
  • [ISO-abbreviation] J Pain Symptom Manage
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Analgesics, Opioid; 0 / Delayed-Action Preparations; 0 / Placebos; 76I7G6D29C / Morphine
  •  go-up   go-down


54. Ansari RH, Edelman MJ, Belani CP, Socinski MA, Obasaju CK, Monberg MJ, Chen R, Treat J: Outcomes for the elderly (≥70 years) from a three-arm phase III trial of gemcitabine in combination with carboplatin (GC) or paclitaxel (GP) versus paclitaxel plus carboplatin (PC) for advanced non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):8052

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes for the elderly (≥70 years) from a three-arm phase III trial of gemcitabine in combination with carboplatin (GC) or paclitaxel (GP) versus paclitaxel plus carboplatin (PC) for advanced non-small cell lung cancer (NSCLC).
  • : 8052 Background: Approximately 50% of lung cancer patients (pts) are ≥ 70 y, however, this population has been historically underrepresented in clinical trials.
  • CONCLUSIONS: In this trial of commonly used regimens for advanced NSCLC, pts 70-74 years of age had significantly longer survival than pts 75-79 years of age.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962865.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Fuse N, Fukuda H, Yamada Y, Sawaki A, Koizumi W, Suzuki Y, Yamaguchi K, Takiuchi H, Ohtsu A, Boku N, Gastrointestinal Oncology Study Group/Japan Clinical Oncology Group: Updated results of randomized phase III study of 5-fluorouracil (5-FU) alone versus combination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer (JCOG 9912). J Clin Oncol; 2009 May 20;27(15_suppl):4514

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Updated results of randomized phase III study of 5-fluorouracil (5-FU) alone versus combination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer (JCOG 9912).
  • CONCLUSIONS: The updated results reconfirmed the primary conclusion that S-1 monotherapy can be a new standard regimen for advanced gastric cancer, and suggest that CP is still worthy for further clinical investigation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962701.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Yennurajalingam S, Palmer JL, Zhang T, Poulter V, Bruera E: Association between fatigue and other cancer-related symptoms in patients with advanced cancer. Support Care Cancer; 2008 Oct;16(10):1125-30
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association between fatigue and other cancer-related symptoms in patients with advanced cancer.
  • GOALS OF WORK: Although fatigue is the chronic symptom most commonly experienced by patients with advanced cancer, little research has been done on the associations and correlates of fatigue in this population.
  • The aim of this study was, therefore, to determine whether fatigue scores, as measured by the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), are associated with age, gender, type of cancer diagnosed, pain, and other cancer-related symptoms measured using the Edmonton Symptom Assessment Scale (ESAS).
  • MATERIALS AND METHODS: We retrospectively reviewed the FACIT-F (when a higher score denotes lower fatigue) and ESAS (when a lower fatigue score denotes lower fatigue intensity) scores of 268 patients with advanced cancer who had been previously enrolled in clinical trials of therapies for fatigue.
  • RESULTS: We found no univariate association between fatigue score and gender, ethnicity (p = 0.31), or type of cancer diagnosed.

  • MedlinePlus Health Information. consumer health - Fatigue.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2007 Aug 10;25(23):3475-81 [17687152.001]
  • [Cites] Palliat Med. 2008 Jan;22(1):13-32 [18216074.001]
  • [Cites] Crit Rev Oncol Hematol. 2003 Sep;47(3):273-9 [12962901.001]
  • [Cites] Support Care Cancer. 1996 Mar;4(2):82-96 [8673356.001]
  • [Cites] J Clin Oncol. 2001 Jul 15;19(14):3385-91 [11454886.001]
  • [Cites] J Clin Oncol. 2006 May 1;24(13):2073-8 [16648508.001]
  • [Cites] J Pain Symptom Manage. 2003 Jul;26(1):604-14 [12850643.001]
  • [Cites] Support Care Cancer. 2008 Aug;16(8):943-6 [18071764.001]
  • [Cites] Oncologist. 2000;5(5):353-60 [11040270.001]
  • [Cites] JAMA. 2007 Jan 17;297(3):295-304 [17227981.001]
  • [Cites] J Palliat Med. 2005 Dec;8(6):1144-9 [16351527.001]
  • [Cites] Eur J Cancer. 2007 Apr;43(6):1030-6 [17336052.001]
  • [Cites] J Clin Oncol. 1993 Mar;11(3):570-9 [8445433.001]
  • [Cites] J Palliat Care. 1991 Summer;7(2):6-9 [1714502.001]
  • [Cites] Sch Inq Nurs Pract. 2000 Winter;14(4):275-90; discussion 291-8 [11372188.001]
  • [Cites] J Psychiatr Res. 1975 Nov;12(3):189-98 [1202204.001]
  • [Cites] J Clin Oncol. 2003 Dec 1;21(23):4439-43 [14645434.001]
  • [Cites] Cancer. 2002 Jan 15;94(2):528-38 [11900238.001]
  • [Cites] J Pain Symptom Manage. 1992 May;7(4):192-5 [1517640.001]
  • [Cites] Cancer. 2000 May 1;88(9):2164-71 [10813730.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(4):743-53 [10673515.001]
  • [Cites] Cancer. 2005 Jan 15;103(2):377-82 [15558809.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1319-28 [11870175.001]
  • [Cites] Ann Oncol. 2000 May;11(5):561-7 [10907949.001]
  • [Cites] J Pain Symptom Manage. 2001 Jun;21(6):456-66 [11397603.001]
  • [Cites] Semin Hematol. 1997 Jul;34(3 Suppl 2):4-12 [9253778.001]
  • [Cites] J Pain Symptom Manage. 2006 Mar;31(3):229-41 [16563317.001]
  • (PMID = 18504622.001).
  • [ISSN] 0941-4355
  • [Journal-full-title] Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  • [ISO-abbreviation] Support Care Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01CA1222292.01; United States / NCI NIH HHS / CA / R01CA124481-01; United States / NINR NIH HHS / NR / R01NR010162-01A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


57. Bakitas M, Lyons KD, Hegel MT, Balan S, Brokaw FC, Seville J, Hull JG, Li Z, Tosteson TD, Byock IR, Ahles TA: Effects of a palliative care intervention on clinical outcomes in patients with advanced cancer: the Project ENABLE II randomized controlled trial. JAMA; 2009 Aug 19;302(7):741-9
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of a palliative care intervention on clinical outcomes in patients with advanced cancer: the Project ENABLE II randomized controlled trial.
  • CONTEXT: There are few randomized controlled trials on the effectiveness of palliative care interventions to improve the care of patients with advanced cancer.
  • OBJECTIVE: To determine the effect of a nursing-led intervention on quality of life, symptom intensity, mood, and resource use in patients with advanced cancer.
  • DESIGN, SETTING, AND PARTICIPANTS: Randomized controlled trial conducted from November 2003 through May 2008 of 322 patients with advanced cancer in a rural, National Cancer Institute-designated comprehensive cancer center in New Hampshire and affiliated outreach clinics and a VA medical center in Vermont.
  • INTERVENTIONS: A multicomponent, psychoeducational intervention (Project ENABLE [Educate, Nurture, Advise, Before Life Ends]) conducted by advanced practice nurses consisting of 4 weekly educational sessions and monthly follow-up sessions until death or study completion (n = 161) vs usual care (n = 161).
  • RESULTS: A total of 322 participants with cancer of the gastrointestinal tract (41%; 67 in the usual care group vs 66 in the intervention group), lung (36%; 58 vs 59), genitourinary tract (12%; 20 vs 19), and breast (10%; 16 vs 17) were randomized.

  • MedlinePlus Health Information. consumer health - Palliative Care.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] JAMA. 2008 Oct 8;300(14):1665-73 [18840840.001]
  • [Cites] Arch Intern Med. 2008 Sep 8;168(16):1783-90 [18779466.001]
  • [Cites] J Clin Oncol. 2009 Jan 10;27(2):206-13 [19064979.001]
  • [Cites] Palliat Support Care. 2009 Mar;7(1):75-86 [19619377.001]
  • [Cites] J Pain Symptom Manage. 2009 Jan;37(1):23-32 [18504093.001]
  • [Cites] J Clin Oncol. 2008 Aug 10;26(23):3860-6 [18688053.001]
  • [Cites] Ann Intern Med. 2000 May 16;132(10):825-32 [10819707.001]
  • [Cites] JAMA. 2000 Nov 15;284(19):2476-82 [11074777.001]
  • [Cites] Pharmacoeconomics. 2000 Nov;18(5):419-23 [11151395.001]
  • [Cites] J Pain Symptom Manage. 2001 Jul;22(1):584-90 [11516600.001]
  • [Cites] J Pain Symptom Manage. 2001 Sep;22(3):727-37 [11532586.001]
  • [Cites] Health Aff (Millwood). 2001 Nov-Dec;20(6):64-78 [11816692.001]
  • [Cites] Cancer Control. 2001 Nov-Dec;8(6 Suppl 2):88-93 [11760564.001]
  • [Cites] Qual Life Res. 2002 May;11(3):207-21 [12074259.001]
  • [Cites] JAMA. 2003 Jun 18;289(23):3106-16 [12813116.001]
  • [Cites] J Palliat Med. 2003 Oct;6(5):699-705 [14622449.001]
  • [Cites] Arch Intern Med. 2004 Jan 12;164(1):83-91 [14718327.001]
  • [Cites] J Palliat Med. 2004 Feb;7(1):119-34 [15000796.001]
  • [Cites] BMJ. 2004 Mar 13;328(7440):607 [15016692.001]
  • [Cites] Oncol Nurs Forum. 2004 Mar-Apr;31(2):313-9 [15017447.001]
  • [Cites] J Palliat Med. 2004 Apr;7(2):363-72 [15130218.001]
  • [Cites] N Engl J Med. 2004 Jun 17;350(25):2582-90 [15201415.001]
  • [Cites] Health Serv Res. 2004 Aug;39(4 Pt 1):1005-26 [15230939.001]
  • [Cites] Lancet. 1984 Apr 21;1(8382):890-4 [6143195.001]
  • [Cites] J Palliat Care. 1991 Summer;7(2):6-9 [1714502.001]
  • [Cites] J Am Geriatr Soc. 1992 Jul;40(7):697-702 [1607586.001]
  • [Cites] BMJ. 1992 Nov 28;305(6865):1317-22 [1483075.001]
  • [Cites] Psychol Rep. 1996 Dec;79(3 Pt 1):1059-69 [8969117.001]
  • [Cites] Cancer Pract. 1997 May-Jun;5(3):147-54 [9171550.001]
  • [Cites] J Clin Oncol. 1998 May;16(5):1986-96 [9586919.001]
  • [Cites] Hosp J. 1998;13(1-2):71-87 [9644394.001]
  • [Cites] Jt Comm J Qual Improv. 1998 Oct;24(10):513-7 [9801950.001]
  • [Cites] Eff Clin Pract. 1998 Aug-Sep;1(1):2-4 [10345255.001]
  • [Cites] J Clin Oncol. 2005 Apr 20;23(12):2637-44 [15728219.001]
  • [Cites] J Clin Oncol. 2005 Apr 20;23(12):2588-9 [15728223.001]
  • [Cites] J Altern Complement Med. 2005;11 Suppl 1:S7-15 [16332190.001]
  • [Cites] J Palliat Med. 2006 Feb;9(1):137-51 [16430353.001]
  • [Cites] J Pain Symptom Manage. 2006 Mar;31(3):270-84 [16563321.001]
  • [Cites] Health Promot Int. 2006 Sep;21(3):245-55 [16751630.001]
  • [Cites] Health Qual Life Outcomes. 2006;4:54 [16925807.001]
  • [Cites] Am J Manag Care. 2007 Feb;13(2):84-92 [17286528.001]
  • [Cites] J Pain Symptom Manage. 2007 Mar;33(3):238-46 [17349493.001]
  • [Cites] J Palliat Med. 2007 Apr;10(2):381-9 [17472510.001]
  • [Cites] J Clin Nurs. 2007 Mar;16(3A):95-104 [17518874.001]
  • [Cites] J Clin Oncol. 2007 Jun 10;25(17):2377-82 [17557950.001]
  • [Cites] Cancer. 2007 Jul 1;110(1):196-202 [17546575.001]
  • [Cites] J Pain Symptom Manage. 2007 Jul;34(1 Suppl):S7-S19 [17532180.001]
  • [Cites] J Pain Symptom Manage. 2007 Aug;34(2):120-5 [17583469.001]
  • [Cites] Prev Med. 2007 Oct;45(4):252-61 [17643481.001]
  • [Cites] Clin Cancer Res. 2008 Apr 1;14(7):2111-8 [18381952.001]
  • [Cites] JAMA. 2008 Apr 9;299(14):1698-709 [18398082.001]
  • [Cites] Cancer. 2008 Apr 15;112(8):1854-61 [18306393.001]
  • [Cites] BMC Psychiatry. 2008;8:60 [18647396.001]
  • [Cites] J Clin Oncol. 2008 Aug 10;26(23):3832-7 [18688049.001]
  • [CommentIn] Evid Based Nurs. 2010 Feb;13(1):9-10 [20179053.001]
  • [CommentIn] JAMA. 2009 Dec 16;302(23):2551; author reply 2551 [20009052.001]
  • (PMID = 19690306.001).
  • [ISSN] 1538-3598
  • [Journal-full-title] JAMA
  • [ISO-abbreviation] JAMA
  • [Language] ENG
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00253383
  • [Grant] United States / NCI NIH HHS / CA / R01 CA101704; United States / NCI NIH HHS / CA / P30 CA023108; United States / NINR NIH HHS / NR / R01 NR011871; United States / NINR NIH HHS / NR / T32 NR008346; United States / NINR NIH HHS / NR / T32NR008346
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS458527; NLM/ PMC3657724
  •  go-up   go-down


58. Clayton JM, Butow PN, Tattersall MH, Devine RJ, Simpson JM, Aggarwal G, Clark KJ, Currow DC, Elliott LM, Lacey J, Lee PG, Noel MA: Randomized controlled trial of a prompt list to help advanced cancer patients and their caregivers to ask questions about prognosis and end-of-life care. J Clin Oncol; 2007 Feb 20;25(6):715-23
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized controlled trial of a prompt list to help advanced cancer patients and their caregivers to ask questions about prognosis and end-of-life care.
  • PURPOSE: To determine whether provision of a question prompt list (QPL) influences advanced cancer patients'/caregivers' questions and discussion of topics relevant to end-of-life care during consultations with a palliative care (PC) physician.
  • Consecutive eligible patients with advanced cancer referred to 15 PC physicians from nine Australian PC services were invited to participate.
  • CONCLUSION: Providing a QPL and physician endorsement of its use assists terminally ill cancer patients and their caregivers to ask questions and promotes discussion about prognosis and end-of-life issues, without creating patient anxiety or impairing satisfaction.

  • MedlinePlus Health Information. consumer health - Cancer--Living with Cancer.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Nat Clin Pract Oncol. 2007 Oct;4(10):562-3 [17700555.001]
  • (PMID = 17308275.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


59. Kimura R, Hashiguchi S, Kawa M, Miyashita M, Sasahara T, Shirai Y, Kazuma K: Pain management and related factors in advanced cancer patients who initiated opioid therapy in an outpatient setting. Palliat Support Care; 2005 Dec;3(4):301-9
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pain management and related factors in advanced cancer patients who initiated opioid therapy in an outpatient setting.
  • OBJECTIVE: The aim of this study was to clarify the state of pain management in Japanese patients with advanced cancer who initiated opioid therapy in an outpatient setting.
  • SIGNIFICANCE OF RESULTS: Result of this study indicated insufficient pain relief at an outpatients setting with advanced cancer patients.

  • MedlinePlus Health Information. consumer health - Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17039985.001).
  • [ISSN] 1478-9515
  • [Journal-full-title] Palliative & supportive care
  • [ISO-abbreviation] Palliat Support Care
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Analgesics, Opioid
  •  go-up   go-down


60. Wu LC, Zhang WD: Clinical Trials of Antiangiogenesis Therapy on Gastric Cancer. Gastroenterology Res; 2008 Dec;1(1):14-19

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical Trials of Antiangiogenesis Therapy on Gastric Cancer.
  • : Both malignant tumor growth and metastasis are dependent upon angiogenesis, a process of new blood vessel formation.
  • A wide variety of angiogenesis inhibitors have been identified and some of them are under clinical trials in the advanced patients with cancer including gastric cancer.
  • This review summarizes the development and progress of angiogenesis inhibitors in recent decades, and discusses the future direction of antiangiogenesis research, and the potential antiangiogenic agents which are most likely to be translated into standard treatment for gastrointestinal cancer patients either alone or combined with other therapies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27994701.001).
  • [ISSN] 1918-2805
  • [Journal-full-title] Gastroenterology research
  • [ISO-abbreviation] Gastroenterology Res
  • [Language] eng
  • [Publication-type] Review; Journal Article
  • [Publication-country] Canada
  • [Keywords] NOTNLM ; angiogenesis inhibitor / clinical trial / gastric cancer
  •  go-up   go-down


61. Herbst RS, Eckhardt SG, Kurzrock R, Ebbinghaus S, O'Dwyer PJ, Gordon MS, Novotny W, Goldwasser MA, Tohnya TM, Lum BL, Ashkenazi A, Jubb AM, Mendelson DS: Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol; 2010 Jun 10;28(17):2839-46
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer.
  • Recombinant human Apo2L/TRAIL (rhApo2L/TRAIL) has broad potential as a cancer therapy.
  • To the best of our knowledge, this is the first in-human clinical trial to assess the safety, tolerability, pharmacokinetics, and antitumor activity of multiple intravenous doses of rhApo2L/TRAIL in patients with advanced cancer.
  • PATIENTS AND METHODS: This phase I, open-label, dose-escalation study treated patients with advanced cancer with rhApo2L/TRAIL doses ranging from 0.5 to 30 mg/kg/d, with parallel dose escalation for patients without liver metastases and with normal liver function (cohort 1) and for patients with liver metastases and normal or mildly abnormal liver function (cohort 2).

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20458040.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Recombinant Proteins; 0 / TNF-Related Apoptosis-Inducing Ligand; 0 / TNFSF10 protein, human
  •  go-up   go-down


62. Elsayem AF, Hui D, Li Z, Flores M, Atkinson WA 4th, Bruera E: Acute palliative care unit in a comprehensive cancer center (CCC): Financial and clinical outcomes. J Clin Oncol; 2009 May 20;27(15_suppl):e20518

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute palliative care unit in a comprehensive cancer center (CCC): Financial and clinical outcomes.
  • : e20518 Background: Acute palliative care units (APCU) in CCCs improves symptom control for advanced cancer patients and supports their families.
  • However, these services are not available in the majority of cancer centers.
  • Further research is needed to investigate possible reasons for lack of APCU in cancer centers.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960912.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Soto-Cárdenas MJ, Pelayo-García G, Rodríguez-Camacho A, Segura-Fernández E, Mogollo-Galván A, Giron-Gonzalez JA: Venous thromboembolism in patients with advanced cancer under palliative care: additional risk factors, primary/secondary prophylaxis and complications observed under normal clinical practice. Palliat Med; 2008 Dec;22(8):965-8
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Venous thromboembolism in patients with advanced cancer under palliative care: additional risk factors, primary/secondary prophylaxis and complications observed under normal clinical practice.
  • Patients with advanced cancer under palliative care (PC) and with VTE, were reviewed during the three years before the study.
  • In PC patients with advanced cancer, VTE is a serious complication that conditions control of symptoms.

  • MedlinePlus Health Information. consumer health - Blood Thinners.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18952751.001).
  • [ISSN] 1477-030X
  • [Journal-full-title] Palliative medicine
  • [ISO-abbreviation] Palliat Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anticoagulants; 0 / Fibrinolytic Agents; 0 / Heparin, Low-Molecular-Weight
  •  go-up   go-down


64. Sideras K, Schaefer PL, Okuno SH, Sloan JA, Kutteh L, Fitch TR, Dakhil SR, Levitt R, Alberts SR, Morton RF, Rowland KM, Novotny PJ, Loprinzi CL: Low-molecular-weight heparin in patients with advanced cancer: a phase 3 clinical trial. Mayo Clin Proc; 2006 Jun;81(6):758-67
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-molecular-weight heparin in patients with advanced cancer: a phase 3 clinical trial.
  • OBJECTIVE: To prospectively assess whether low-molecular-weight heparin (LMWH) provides a survival benefit in patients with advanced cancer.
  • PATIENTS AND METHODS: Between December 1998 and June 2001, we performed a randomized controlled study of patients with advanced cancer.

  • MedlinePlus Health Information. consumer health - Blood Thinners.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16770976.001).
  • [ISSN] 0025-6196
  • [Journal-full-title] Mayo Clinic proceedings
  • [ISO-abbreviation] Mayo Clin. Proc.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-15083; United States / NCI NIH HHS / CA / CA-25224; United States / NCI NIH HHS / CA / CA-35101; United States / NCI NIH HHS / CA / CA-35195; United States / NCI NIH HHS / CA / CA-35431; United States / NCI NIH HHS / CA / CA-37404; United States / NCI NIH HHS / CA / CA-37417; United States / NCI NIH HHS / CA / CA-52352; United States / NCI NIH HHS / CA / CA-60276; United States / NCI NIH HHS / CA / CA-63826
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticoagulants; S79O08V79F / Dalteparin
  •  go-up   go-down


65. Rudolf E, Klvačová L, John S, Červinka M: Zinc Alters Cytoskeletal Integrity and Migration in Colon Cancer Cells. Acta Medica (Hradec Kralove); 2008;51(1):51-57

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Zinc Alters Cytoskeletal Integrity and Migration in Colon Cancer Cells.
  • Zinc has been shown to have inhibitory effects on proliferation and metabolism of malignant colonocytes.
  • Still, there is no information available concerning putative effects of zinc against motility and migration of colon cancer cells.
  • These results emphasize the possible multitudinous role of zinc in the process of colon cancer development and hint at the potential of this element in chemoprevention of advanced colorectal carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28632128.001).
  • [ISSN] 1211-4286
  • [Journal-full-title] Acta medica (Hradec Kralove)
  • [ISO-abbreviation] Acta Medica (Hradec Kralove)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Czech Republic
  • [Keywords] NOTNLM ; Cytokeleton / Invasion / Microtubules / Migration / SW480 cells
  •  go-up   go-down


66. Bowman KF, Rose JH, Radziewicz RM, O'Toole EE, Berila RA: Family caregiver engagement in a coping and communication support intervention tailored to advanced cancer patients and families. Cancer Nurs; 2009 Jan-Feb;32(1):73-81
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Family caregiver engagement in a coping and communication support intervention tailored to advanced cancer patients and families.
  • We describe family caregiver (FCG) participation in a tailored coping and communication support intervention for advanced cancer patients and families.
  • Findings will guide modification and dissemination of this intervention primarily in cancer clinics for the underserved.

  • MedlinePlus Health Information. consumer health - Caregivers.
  • MedlinePlus Health Information. consumer health - Family Issues.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19104204.001).
  • [ISSN] 1538-9804
  • [Journal-full-title] Cancer nursing
  • [ISO-abbreviation] Cancer Nurs
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA102828; United States / NCI NIH HHS / CA / R01-CA10282
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


67. Dewey A, Dean T: Assessment and monitoring of nutritional status in patients with advanced cancer: part 1. Int J Palliat Nurs; 2007 Jun;13(6):258-65
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment and monitoring of nutritional status in patients with advanced cancer: part 1.
  • Using a qualitative approach, this study set out to explore nurses' management of patients with advanced cancer, weight loss and eating-associated problems.
  • Extreme weight loss is commonly seen in patients with incurable solid tumour cancer and, to date, it has proved difficult to manage successfully.
  • Many nurses were reluctant to initiate conversations with cancer patients about weight loss, but instead waited for patients and relatives to raise their concerns.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17851381.001).
  • [ISSN] 1357-6321
  • [Journal-full-title] International journal of palliative nursing
  • [ISO-abbreviation] Int J Palliat Nurs
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


68. Rowlands J, Noble S: How does the environment impact on the quality of life of advanced cancer patients? A qualitative study with implications for ward design. Palliat Med; 2008 Sep;22(6):768-74

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] How does the environment impact on the quality of life of advanced cancer patients? A qualitative study with implications for ward design.
  • The aim of this study is to explore the views of patients with advanced cancer on the effect the ward environment has on their overall well-being.
  • Semi-structured interviews exploring the experiences of 12 inpatients at a regional cancer centre were recorded and transcribed verbatim.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18715977.001).
  • [ISSN] 1477-030X
  • [Journal-full-title] Palliative medicine
  • [ISO-abbreviation] Palliat Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


69. Bausewein C, Booth S, Gysels M, Kühnbach R, Haberland B, Higginson IJ: Individual breathlessness trajectories do not match summary trajectories in advanced cancer and chronic obstructive pulmonary disease: results from a longitudinal study. Palliat Med; 2010 Dec;24(8):777-86
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Individual breathlessness trajectories do not match summary trajectories in advanced cancer and chronic obstructive pulmonary disease: results from a longitudinal study.
  • Breathlessness is a distressing symptom in advanced disease.
  • This study aimed to describe and compare the summary and individual trajectories of breathlessness and overall symptom burden over time and towards the end of life following patients with advanced cancer or severe chronic obstructive pulmonary disease (COPD) in inpatient and outpatient health care settings in Germany.
  • Forty-nine cancer and 60 COPD patients were included.
  • Thirty out of the 49 cancer and 6/60 COPD patients died, 7/49 cancer and 20/60 COPD patients dropped out due to physical deterioration or questionnaire fatigue.
  • In cancer patients, breathlessness increased towards death.
  • Twenty-one cancer and 43 COPD patients provided data for individual breathlessness trajectories.


70. Smith M, Kutner J, Hemphill L, Yamashita T, Felton S: Developing treatment and control conditions in a clinical trial of massage therapy for advanced cancer. J Soc Integr Oncol; 2007;5(4):139-46
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Developing treatment and control conditions in a clinical trial of massage therapy for advanced cancer.
  • The purpose of this article is to describe the challenges faced by a research team in developing treatment and control conditions in a study of the efficacy of massage therapy for advanced cancer.

  • MedlinePlus Health Information. consumer health - Clinical Trials.
  • MedlinePlus Health Information. consumer health - Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19087757.001).
  • [ISSN] 1715-894X
  • [Journal-full-title] Journal of the Society for Integrative Oncology
  • [ISO-abbreviation] J Soc Integr Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  •  go-up   go-down


71. Walsh D, Perin ML, McIver B: Parenteral morphine prescribing patterns among inpatients with pain from advanced cancer: a prospective survey of intravenous and subcutaneous use. Am J Hosp Palliat Care; 2006 Oct-Nov;23(5):353-9
Hazardous Substances Data Bank. MORPHINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Parenteral morphine prescribing patterns among inpatients with pain from advanced cancer: a prospective survey of intravenous and subcutaneous use.
  • Prescribing patterns for parenteral morphine for symptom control in advanced cancer were studied in 50 consecutive hospital admissions (27 men, 23 women, median age, 62 years).
  • These patterns of parenteral morphine application reflect the complexity of the challenge presented by the various cancer pain syndromes.

  • MedlinePlus Health Information. consumer health - Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17060302.001).
  • [ISSN] 1049-9091
  • [Journal-full-title] The American journal of hospice & palliative care
  • [ISO-abbreviation] Am J Hosp Palliat Care
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Analgesics, Opioid; 76I7G6D29C / Morphine
  •  go-up   go-down


72. Dy SM, Apostol CC: Evidence-based approaches to other symptoms in advanced cancer. Cancer J; 2010 Sep-Oct;16(5):507-13
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evidence-based approaches to other symptoms in advanced cancer.
  • Dyspnea, nausea and vomiting, anorexia, fatigue, and sleep disturbances are common and distressing in advanced cancer.
  • The strongest evidence supports metoclopramide for cancer-related nausea and octreotide for bowel obstruction.
  • For insomnia, evidence supports cognitive-behavioral therapy in cancer; no sleep agents have superior effectiveness.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20890148.001).
  • [ISSN] 1540-336X
  • [Journal-full-title] Cancer journal (Sudbury, Mass.)
  • [ISO-abbreviation] Cancer J
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  •  go-up   go-down


73. Koffman J, Morgan M, Edmonds P, Speck P, Higginson I: Cultural meanings of pain: a qualitative study of Black Caribbean and White British patients with advanced cancer. Palliat Med; 2008 Jun;22(4):350-9
MedlinePlus Health Information. consumer health - Cancer--Living with Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cultural meanings of pain: a qualitative study of Black Caribbean and White British patients with advanced cancer.
  • Pain is a common cancer-related symptom, but little research has been conducted that explores the meanings of this symptom across different ethnic groups.
  • This study involved qualitative interviews to explore and compare the meanings of pain among 26 Black Caribbean and 19 White patients with advanced cancer.
  • A total of 23/26 Black Caribbean and 15/19 White patients reported cancer-related pain.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18541639.001).
  • [ISSN] 0269-2163
  • [Journal-full-title] Palliative medicine
  • [ISO-abbreviation] Palliat Med
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


74. Radziewicz RM, Rose JH, Bowman KF, Berila RA, O'Toole EE, Given B: Establishing treatment fidelity in a coping and communication support telephone intervention for aging patients with advanced cancer and their family caregivers. Cancer Nurs; 2009 May-Jun;32(3):193-202
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Establishing treatment fidelity in a coping and communication support telephone intervention for aging patients with advanced cancer and their family caregivers.
  • A randomized controlled trial of a nurse-delivered coping and communication support (CCS) intervention tailored to the preferences of middle-aged and older patients with advanced cancer and their family caregivers is tested for its value in improving outcomes for quality cancer care.

  • MedlinePlus Health Information. consumer health - Cancer--Living with Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19295420.001).
  • [ISSN] 1538-9804
  • [Journal-full-title] Cancer nursing
  • [ISO-abbreviation] Cancer Nurs
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA102828; United States / NCI NIH HHS / CA / R01-CA10282
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] United States
  • [Number-of-references] 28
  •  go-up   go-down


75. Aboziada MA, El-Sayed MI, Maximous DW, Abdel-Wanis ME, Bakr MM: Feasibility of breast conservation after neoadjuvant taxae-based chemotherapy in locally advanced breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e11627

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Feasibility of breast conservation after neoadjuvant taxae-based chemotherapy in locally advanced breast cancer.
  • : e11627 Background: Neoadjuvant chemotherapy is the standard of care of locally advanced cancer breast.
  • CONCLUSIONS: Breast conservation is feasible in selected cases of locally advanced, non metastatic cancer breast.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961121.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Kim Y, Lee J, Choi W, Park J, Kim H, Lee S, Kim D, Lee J, Bang Y, Heo DS: Effect of interval between diagnosis of advanced cancer and cessation of active anti-cancer treatment on survival in terminally ill cancer patients. J Clin Oncol; 2009 May 20;27(15_suppl):e20630

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of interval between diagnosis of advanced cancer and cessation of active anti-cancer treatment on survival in terminally ill cancer patients.
  • : e20630 Background: Although various prognostic factors have been proposed to predict survival in terminally ill cancer patients, accurate prognostication is still a challenging task for oncologists.
  • The objective of this study was to evaluate whether the time interval between diagnosis of advanced cancer and cessation of active anti-cancer treatment (ATP; active treatment period) can predict survival in terminally ill cancer patients.
  • METHODS: We prospectively evaluated 79 patients with advanced (recurrent or metastatic) cancer who were determined as terminal stage, namely cessation of active anti-cancer treatment and transition to palliative care, by attending oncologists.
  • Median overall survival after being diagnosed with advanced cancer was 11.6 months (95% confidence interval (CI), 8.02-15.18), and survival after being determined as terminal stage was 1.9 months (95% CI, 1.38-2.42).
  • On multivariate analysis, short ATP, non-colorectal cancer, fatigue, and Karnofsky performance status less than 50 were significantly associated with a poor prognosis.
  • CONCLUSIONS: Our study suggests that ATP is an independent prognostic factor for survival in terminally ill cancer patients who cannot receive active anti-cancer treatment anymore.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961582.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


77. Acres B, Quoix E, Ramlau R, Lacoste G, Marie Bastien B, Tavernaro A, Bettinger S, Bizouarne N, Limacher JM, Bonnefoy JY: Biomarkers associated with clinical outcome in advanced non-small cell lung cancer patients treated with TG4010. J Clin Oncol; 2009 May 20;27(15_suppl):3027

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biomarkers associated with clinical outcome in advanced non-small cell lung cancer patients treated with TG4010.
  • It was tested in combination with first-line chemotherapy in a randomized, controlled, multicenter phase II study in patients with advanced non small cell lung cancer (NSCLC) (ASCO 2008- Abstract No 8023) Methods: In addition to clinical endpoints, immune parameters were tested.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962065.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


78. Flood WA, Lewis LD: A phase I study of intravenous (IV) milataxel in combination with carboplatin in adult patients with advanced malignant solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):e13525

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I study of intravenous (IV) milataxel in combination with carboplatin in adult patients with advanced malignant solid tumors.
  • The primary objective of this study was to determine the MTD when MXL was given intravenously in combination with a fixed dose (AUC=6) of carboplatin (C) every 21 days in subjects with advanced malignant solid tumors.
  • METHODS: Key subject eligibility criteria included: adult pts with refractory malignant tumors, ECOG PS <3 and adequate hematologic, hepatic and renal function.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961283.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


79. Iwase H, Yamamoto Y, Kurebayashi J, Tsuda H, Ota T, Kurosumi M, Miyamoto K, Iwase T, Research Group of the Japanese Breast Cancer Society: Clinicopathologic and prognostic features of triple-negative breast cancer analyzed in registration data of the Japanese Breast Cancer Society, 11705 cases. J Clin Oncol; 2009 May 20;27(15_suppl):e22122

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic and prognostic features of triple-negative breast cancer analyzed in registration data of the Japanese Breast Cancer Society, 11705 cases.
  • To clarify the characteristics of TN tumors, the data of the registration committee of the Japanese Breast Cancer Society were analyzed with respect to clinicopathologic factors, response to neoadjuvant chemotherapy (NAC) and prognosis.
  • TN cancers were diagnosed at a slightly advanced stage and more of the cases had lymph node metastases compared to other types.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963560.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Lee JJ, Lee JJ: A phase II study of an herbal decoction that includes Astragali radix for cancer-associated anorexia in patients with advanced cancer. Integr Cancer Ther; 2010 Mar;9(1):24-31
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of an herbal decoction that includes Astragali radix for cancer-associated anorexia in patients with advanced cancer.
  • HYPOTHESIS: Anorexia and cancer cachexia produce significant loss of adipose tissue and muscle mass and eventually reduce survival in cancer patients.
  • STUDY DESIGN: This phase II study was conducted to assess the efficacy and the safety of an herbal decoction with Astragali radix in patients with anorexia in advanced cancer.
  • METHODS: All patients with histologic evidence of an incurable malignancy had a weight loss of at least 5% during the preceding 6 months and a patient-estimated severe anorexia.The herbal decoction was administered 30 minutes after meals, three times a day for 3 weeks.The score of appetite, body weight, the cytokines, IL-1beta, IL-6, TNF-alpha, and anthropometric measurements were assessed.
  • This herbal decoction shows some potential for management of cancer-related anorexia.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. LACTIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20150220.001).
  • [ISSN] 1552-695X
  • [Journal-full-title] Integrative cancer therapies
  • [ISO-abbreviation] Integr Cancer Ther
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Astragali compound; 0 / Cytokines; 0 / Drugs, Chinese Herbal; 33X04XA5AT / Lactic Acid
  •  go-up   go-down


81. Kelly WK, O'Connor OA, Krug LM, Chiao JH, Heaney M, Curley T, MacGregore-Cortelli B, Tong W, Secrist JP, Schwartz L, Richardson S, Chu E, Olgac S, Marks PA, Scher H, Richon VM: Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol; 2005 Jun 10;23(17):3923-31
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer.
  • PURPOSE: To determine the safety, dosing schedules, pharmacokinetic profile, and biologic effect of orally administered histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) in patients with advanced cancer.

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Vorinostat .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 2003 Jan 10;112(1):11-7 [12526789.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] FEBS Lett. 2001 Jun 22;499(3):199-204 [11423116.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Jul;86(7):3430-5 [11443220.001]
  • [Cites] Gene Expr. 1996;5(4-5):245-53 [8723390.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):2860-5 [11854457.001]
  • [Cites] Am J Respir Cell Mol Biol. 2001 Nov;25(5):562-8 [11713097.001]
  • [Cites] J Clin Oncol. 1990 May;8(5):813-9 [2185339.001]
  • [Cites] Cancer. 1981 Jan 1;47(1):207-14 [7459811.001]
  • [Cites] Adv Cancer Res. 2004;91:137-68 [15327890.001]
  • [Cites] Curr Opin Genet Dev. 2002 Apr;12(2):198-209 [11893494.001]
  • [Cites] Nat Genet. 2002 Jun;31(2):141-9 [11992124.001]
  • [Cites] Genome Biol. 2002;3(5):reviews0006 [12049668.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Sep 3;99(18):11700-5 [12189205.001]
  • [Cites] Nat Genet. 2002 Dec;32(4):606-13 [12402037.001]
  • [Cites] Blood. 2003 Apr 15;101(8):2914-23 [12515714.001]
  • [Cites] Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3578-88 [14506144.001]
  • [Cites] Endocrinology. 2004 Jun;145(6):2865-75 [14976143.001]
  • (PMID = 15897550.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA092629; United States / NCI NIH HHS / CA / R21 CA096228; United States / NCI NIH HHS / CA / CA96228-0
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Histone Deacetylase Inhibitors; 0 / Hydroxamic Acids; 58IFB293JI / vorinostat
  • [Other-IDs] NLM/ NIHMS18169; NLM/ PMC1855284
  •  go-up   go-down


82. Nekolaichuk CL, Fainsinger RL, Lawlor PG: A validation study of a pain classification system for advanced cancer patients using content experts: the Edmonton Classification System for Cancer Pain. Palliat Med; 2005 Sep;19(6):466-76
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A validation study of a pain classification system for advanced cancer patients using content experts: the Edmonton Classification System for Cancer Pain.
  • The purpose of this study was to gather construct validity evidence for a pain classification system for advanced cancer patients using content experts.
  • To reflect its intended use as a classification system, the name of the instrument was changed to the Edmonton Classification System for Cancer Pain (ECS-CP).

  • MedlinePlus Health Information. consumer health - Pain.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16218159.001).
  • [ISSN] 0269-2163
  • [Journal-full-title] Palliative medicine
  • [ISO-abbreviation] Palliat Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] England
  •  go-up   go-down


83. Briasoulis E, Golfinopoulos V, Karina M, Papakostas P, Pavlidis N, Fountzilas G: Phase I trial of weekly irinotecan and paclitaxel combined with carboplatin in patients with advanced cancer: a Hellenic Cooperative Oncology Group Study. Anticancer Drugs; 2010 Sep;21(8):785-9
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I trial of weekly irinotecan and paclitaxel combined with carboplatin in patients with advanced cancer: a Hellenic Cooperative Oncology Group Study.
  • This trial aimed to define a recommended safe dose (RSD) of weekly paclitaxel and irinotecan combined with carboplatin in patients with advanced cancer.
  • Patients with advanced cancer were eligible for this trial.
  • [MeSH-minor] Adult. Aged. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Neoplasm Staging. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20647930.001).
  • [ISSN] 1473-5741
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 7673326042 / irinotecan; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


84. Watanabe H, Leki R, Mori K, Takada Y, Nishiwaki Y, Saijo N, Fukuoka M: Tumor response category for the indicator of prognosis: Analysis of survival data in a Four-Arm Cooperative Study (FACS) for advanced non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):8088

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor response category for the indicator of prognosis: Analysis of survival data in a Four-Arm Cooperative Study (FACS) for advanced non-small cell lung cancer (NSCLC).
  • To evaluate whether the tumor response category might be used as an indicator of the prognosis, we conducted an analysis of the best overall response and survival data obtained from FACS, a phase III randomized trial comparing four platinum-based regimens for advanced NSCLC.
  • METHODS: A total of 602 patients (pts) with advanced NSCLC from 44 hospitals in Japan were registered in FACS.
  • CONCLUSIONS: The disease control rate was a more sensitive indicator of the prognosis than the response rate in pts with advanced NSCLC registered in FACS.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962665.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


85. Kang S, Hwang Y, Lee H, Jeong S, Choi J, Jo Y, Han S, Kim J, Han J: Helicobacter pylori infection as an independent prognostic factor for locally advanced gastric cancer with curative resection. J Clin Oncol; 2009 May 20;27(15_suppl):4562

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Helicobacter pylori infection as an independent prognostic factor for locally advanced gastric cancer with curative resection.
  • : 4562 Background: A few studies reported the association between helicobacter pylori (HP) infection and better overall survival (OS) in resected gastric cancer patients (pts).
  • METHODS: We investigated the HP infection status and its association with clinicopathologic characteristics in 210 locally advanced gastric cancer patients (stage IB: 18, II: 61, IIIA: 62, IIIB: 31, IV: 38) who underwent adjuvant chemotherapy (CTX) after curative resection (≥D2 dissection).
  • Twenty-two pts received 5-FU, doxorubicin (DOX) CTX (5- FU 500 mg/m2 weekly for 36 wks, DOX 40 mg/m2 q 3 weeks x 12) with or without OK432, while 188 pts underwent 5-FU, mitomycin-C (MMC), and polysaccharide-K (PSK) CTX (5-FU 500 mg/m2 weekly for 24 wks, MMC 8 mg/m2 q 6 wks x 4, PSK 3 g/day for 16 wks) (Br J Cancer 84:186, 2001, Hepatogastroenterol 54:290, 2007).
  • In multivariate analysis, HP(-) was the most significant independent prognostic factor of poor OS (hazard ratio 9.646, 95% CI 5.407-17.206, p<0.0001) followed by advanced stage (p=0.032), Bormann type IV (p=0.037) and old age (p=0.015).
  • CONCLUSIONS: HP infection status seems to have strong prognostic significance in locally advanced gastric cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963058.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. Agar M, To T, Plummer J, Abernethy A, Currow D: Anti-cholinergic load, health care utilization, and survival in people with advanced cancer: a pilot study. J Palliat Med; 2010 Jun;13(6):745-52
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anti-cholinergic load, health care utilization, and survival in people with advanced cancer: a pilot study.
  • Anti-cholinergic load associated with medication increases as death approaches in those with advanced cancer, yet little is known about associated adverse outcomes in this setting.
  • METHODS: A substudy of 112 participants in a randomised control trial who had cancer and an Australia modified Karnofsky Performance Scale (AKPS) score (AKPS) of 60 or above, explored survival and health service utilisation; with anti-cholinergic load calculated using the Clinician Rated Anti-cholinergic Scale (modified version) longitudinally to death.
  • [MeSH-major] Cholinergic Antagonists / therapeutic use. Health Services / utilization. Neoplasm Staging. Neoplasms / drug therapy. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20597708.001).
  • [ISSN] 1557-7740
  • [Journal-full-title] Journal of palliative medicine
  • [ISO-abbreviation] J Palliat Med
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cholinergic Antagonists
  •  go-up   go-down


87. Curtis JR, Engelberg R, Young JP, Vig LK, Reinke LF, Wenrich MD, McGrath B, McCown E, Back AL: An approach to understanding the interaction of hope and desire for explicit prognostic information among individuals with severe chronic obstructive pulmonary disease or advanced cancer. J Palliat Med; 2008 May;11(4):610-20
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An approach to understanding the interaction of hope and desire for explicit prognostic information among individuals with severe chronic obstructive pulmonary disease or advanced cancer.
  • METHODS: We conducted in-depth longitudinal qualitative interviews with patients with either advanced cancer or severe chronic obstructive pulmonary disease (COPD), along with their family, physicians, and nurses.


88. Hishinuma S, Ogata Y, Tomikawa M, Ozawa I: Stomach-preserving distal pancreatectomy with combined resection of the celiac artery: radical procedure for locally advanced cancer of the pancreatic body. J Gastrointest Surg; 2007 Jun;11(6):743-9
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stomach-preserving distal pancreatectomy with combined resection of the celiac artery: radical procedure for locally advanced cancer of the pancreatic body.
  • To enhance the resectability of cancer of the pancreatic body, a new surgical technique should be developed.
  • Of 25 patients with cancer of the pancreatic body who underwent distal pancreatectomy with curative intent, seven with cancer invasion around the celiac artery underwent stomach-preserving distal pancreatectomy with combined resection of the celiac artery.
  • The present study suggests that this surgical procedure is a rational approach to locally advanced pancreatic body cancer invading around the celiac artery.
  • In view of the feasibility of this procedure, it can also be adopted for less advanced cancer of the pancreatic body to enhance local control and survival.

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17417712.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


89. Rustin GJ, Shreeves G, Nathan PD, Gaya A, Ganesan TS, Wang D, Boxall J, Poupard L, Chaplin DJ, Stratford MR, Balkissoon J, Zweifel M: A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer. Br J Cancer; 2010 Apr 27;102(9):1355-60
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer.
  • METHODS: Patients with advanced cancer refractory to standard therapy were treated with CA4P as a 10-min infusion, 20 h before carboplatin, paclitaxel, or paclitaxel, followed by carboplatin.
  • Responses were seen in 10 of 46 (22%) patients with ovarian, oesophageal, small-cell lung cancer, and melanoma.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Vascul Pharmacol. 2009 Nov-Dec;51(5-6):337-43 [19737629.001]
  • [Cites] Eur J Cancer. 2000 Sep;36(14):1833-43 [10974632.001]
  • [Cites] Radiother Oncol. 2001 Aug;60(2):155-61 [11439210.001]
  • [Cites] Int J Cancer. 2002 May 1;99(1):1-6 [11948484.001]
  • [Cites] Cancer Res. 2002 Jun 15;62(12):3408-16 [12067983.001]
  • [Cites] Br J Cancer. 2003 Apr 22;88(8):1160-7 [12698178.001]
  • [Cites] J Clin Oncol. 2003 May 15;21(10 Suppl):187s-193s [12743133.001]
  • [Cites] J Clin Oncol. 2003 Aug 1;21(15):2815-22 [12807934.001]
  • [Cites] J Clin Oncol. 2003 Aug 1;21(15):2823-30 [12807935.001]
  • [Cites] J Clin Oncol. 2003 Aug 1;21(15):2831-42 [12807936.001]
  • [Cites] J Clin Oncol. 2003 Dec 1;21(23):4428-38 [14645433.001]
  • [Cites] Eur J Cancer. 2004 Jan;40(2):284-90 [14728944.001]
  • [Cites] Anticancer Drugs. 1993 Feb;4(1):19-25 [8457709.001]
  • [Cites] Cancer Res. 1999 Apr 1;59(7):1626-34 [10197639.001]
  • [Cites] J Natl Cancer Inst. 2004 Nov 17;96(22):1682-91 [15547181.001]
  • [Cites] Clin Cancer Res. 2005 Feb 15;11(4):1527-33 [15746056.001]
  • [Cites] Int J Gynecol Cancer. 2006 Jul-Aug;16(4):1557-64 [16884365.001]
  • [Cites] Science. 2006 Sep 22;313(5794):1785-7 [16990548.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 May 1;68(1):211-7 [17448875.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2007 Aug;19(6):443-56 [17459681.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Aug;92(8):2902-9 [17550961.001]
  • [Cites] Anticancer Res. 2000 Jan-Feb;20(1A):229-33 [10769660.001]
  • (PMID = 20389300.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Stilbenes; BG3F62OND5 / Carboplatin; I5590ES2QZ / fosbretabulin; P88XT4IS4D / Paclitaxel
  • [Other-IDs] NLM/ PMC2865759
  •  go-up   go-down


90. Koffman J, Morgan M, Edmonds P, Speck P, Higginson IJ: Vulnerability in palliative care research: findings from a qualitative study of black Caribbean and white British patients with advanced cancer. J Med Ethics; 2009 Jul;35(7):440-4
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vulnerability in palliative care research: findings from a qualitative study of black Caribbean and white British patients with advanced cancer.
  • AIM: To examine issues of vulnerability in cancer and palliative care research obtained through qualitative interviews.
  • METHOD: Secondary analysis of qualitative data from 26 black Caribbean and 19 white British patients with advanced cancer.

  • MedlinePlus Health Information. consumer health - Cancer--Living with Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19567695.001).
  • [ISSN] 1473-4257
  • [Journal-full-title] Journal of medical ethics
  • [ISO-abbreviation] J Med Ethics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


91. Iliopoulou EG, Kountourakis P, Karamouzis MV, Doufexis D, Ardavanis A, Baxevanis CN, Rigatos G, Papamichail M, Perez SA: A phase I trial of adoptive transfer of allogeneic natural killer (NK) cells in patients (pts) with advanced non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):3001

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I trial of adoptive transfer of allogeneic natural killer (NK) cells in patients (pts) with advanced non-small cell lung cancer (NSCLC).
  • Preclinical studies revealed that activated NK cells massively infiltrate lung tissue and improve recipient survival, suggesting a potential role in lung cancer therapeutics.
  • We performed this phase I trial to evaluate safety and antitumor responses of allogeneic, in vitro activated and expanded NK cells in combination with chemotherapy (C) in pts with advanced NSCLC.
  • METHODS: Pts with unresectable locally advanced/metastatic NSCLC receiving 1st/2nd line C were eligible.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962051.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


92. Nielsen DL, Langkjer ST, Bjerre K, Cold S, Stenbygaard L, Soerensen PG, Kamby C: Gemcitabine plus docetaxel versus docetaxel in patients (pts) with HER2-negative locally advanced or metastatic breast cancer (MBC): A randomized phase III study. J Clin Oncol; 2009 May 20;27(15_suppl):1015

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemcitabine plus docetaxel versus docetaxel in patients (pts) with HER2-negative locally advanced or metastatic breast cancer (MBC): A randomized phase III study.
  • METHODS: Females with HER-2-negative locally advanced or MBC and a WHO performance status ≤ 2 were randomized to GT (G 1,000mg/m<sup>2</sup> day 1 + 8; T 75mg/m<sup>2</sup> day 1) or T (100mg/m<sup>2</sup> day 1) every 21 days.
  • CONCLUSIONS: Preliminary data of GT as first- or second-line chemotherapy demonstrates a TTP advantage among HER-2-negative pts with advanced breast cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960732.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


93. Cortés J, Baselga J, Petrella T, Gelmon K, Fumoleau P, Verma S, Pivot X, Ross G, Szado T, Gianni L: Pertuzumab monotherapy following trastuzumab-based treatment: Activity and tolerability in patients with advanced HER2- positive breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):1022

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pertuzumab monotherapy following trastuzumab-based treatment: Activity and tolerability in patients with advanced HER2- positive breast cancer.
  • In 2 cohorts of pts (n = 66) with HER2-positive metastatic breast cancer which had progressed during trastuzumab therapy after ≤3 lines of chemotherapy with or without trastuzumab, pertuzumab plus trastuzumab has been shown to be active (CR 7.6%, PR 16.7%, SD ≥6/12 25.8%) (Gelmon et al.
  • CONCLUSIONS: Pertuzumab monotherapy is active against HER2-positive breast cancer which has progressed during trastuzumab-based therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961043.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


94. Shenkier TN, Hayes M, Gelmon KA, Chia S, Bajdik C, Norris B, Caroline S, Hassell P, O'Reilly SE, Allan S, Yerushalmi R: A phase II trial of a neoadjuvant platinum-containing regimen for locally advanced breast cancer: Pathologic response, long-term follow-up, and correlation with biomarkers. J Clin Oncol; 2009 May 20;27(15_suppl):e11510

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II trial of a neoadjuvant platinum-containing regimen for locally advanced breast cancer: Pathologic response, long-term follow-up, and correlation with biomarkers.
  • : e11510 Background: To determine the response, tolerability, and long-term outcome of a neoadjuvant platinum-containing regimen for locally advanced breast cancer (LABC).
  • Further studies tailored for specific breast cancer subtypes are required.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964639.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


95. Venkitaraman R, Ramanan SG, Rajalekshmy KR, Sagar TG, Shanta V: Predictors of pathologic response to preoperative chemotherapy and concurrent radiotherapy for locally advanced breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e11545

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictors of pathologic response to preoperative chemotherapy and concurrent radiotherapy for locally advanced breast cancer.
  • : e11545 Background: Combined modality treatment is essential for acheiving optimal results in the management of locally advanced breast cancer (LABC).
  • AIM: To determine the rate of pathologic complete response (pCR) after neoadjuvant chemotherapy and radiotherapy for locally advanced breast cancer and to identify the predictors of pCR.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964659.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


96. Bergquist H, Wenger U, Johnsson E, Nyman J, Ejnell H, Hammerlid E, Lundell L, Ruth M: Stent insertion or endoluminal brachytherapy as palliation of patients with advanced cancer of the esophagus and gastroesophageal junction. Results of a randomized, controlled clinical trial. Dis Esophagus; 2005;18(3):131-9
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stent insertion or endoluminal brachytherapy as palliation of patients with advanced cancer of the esophagus and gastroesophageal junction. Results of a randomized, controlled clinical trial.
  • SUMMARY: Esophageal cancer often presents as advanced stage disease with a dismal prognosis, with only 10-15% of patients surviving 5 years.
  • Sixty-five patients with advanced cancer of the esophagus or gastroesophageal junction were randomized to treatment with either an Ultraflex expandable stent or high-dose-rate endoluminal brachytherapy with 7 Gy x 3 given in 2-4 weeks.
  • The HRQL was measured with standardized questionnaires (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Oesophageal Module and Hospital Anxiety and Depression Scale).

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16045572.001).
  • [ISSN] 1120-8694
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


97. Prévost A, Mérol JC, Aimé P, Moutel K, Roger-Liautaud F, Nasca S, Legros M, Coninx P: A randomized trial between two neoadjuvant chemotherapy protocols: CDDP + 5-FU versus CDDP + VP16 in advanced cancer of the head and neck. Oncol Rep; 2005 Sep;14(3):771-6
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized trial between two neoadjuvant chemotherapy protocols: CDDP + 5-FU versus CDDP + VP16 in advanced cancer of the head and neck.
  • We investigated a phase III randomized trial to compare efficacy and tolerance of CDDP + 5-FU to CDDP + VP16, both given intravenously in patients with unresectable advanced head and neck cancer.
  • Although we could not show a benefit in survival with the CDDP + 5-FU protocol, this trial supports literature data and confirms that this regimen may be proposed as a first-line therapy in advanced cancer of the head and neck.

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16077990.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] Greece
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


98. Hui D, Elsayem A, Palla S, De La Cruz M, Li Z, Yennurajalingam S, Bruera E: Discharge outcomes and survival of patients with advanced cancer admitted to an acute palliative care unit at a comprehensive cancer center. J Palliat Med; 2010 Jan;13(1):49-57
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Discharge outcomes and survival of patients with advanced cancer admitted to an acute palliative care unit at a comprehensive cancer center.
  • Demographics, cancer diagnosis, discharge outcomes, and overall survival from discharge were retrieved retrospectively.
  • Multivariate logistic regression revealed that male gender, specific cancer primaries, and admissions from oncology units were associated with death in the APCU, while younger age and direct admissions to the APCU were associated with home discharge.
  • CONCLUSIONS: Our APCU serves patients with advanced cancer with diverse clinical characteristics and survival, and discharged home a significant proportion with survival greater than 6 months.

  • MedlinePlus Health Information. consumer health - Critical Care.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Palliat Med. 2002 Feb;5(1):93-100 [11839231.001]
  • [Cites] Support Care Cancer. 2010 Jan;18(1):67-76 [19350282.001]
  • [Cites] Arch Intern Med. 2004 Jan 12;164(1):83-91 [14718327.001]
  • [Cites] Omega (Westport). 2002;45(4):331-48 [15106653.001]
  • [Cites] J Clin Oncol. 2004 May 15;22(10):2008-14 [15143094.001]
  • [Cites] Cancer Chemother Rep. 1966 Mar;50(3):163-70 [5910392.001]
  • [Cites] Support Care Cancer. 1996 Sep;4(5):329-33 [8883225.001]
  • [Cites] Palliat Med. 1998 Mar;12(2):75-82 [9616443.001]
  • [Cites] J Pain Symptom Manage. 2004 Dec;28(6):548-56 [15589080.001]
  • [Cites] Int J Clin Pract. 2004 Nov;58(11):1014-9 [15605663.001]
  • [Cites] J Pain Symptom Manage. 1999 Oct;18(4):243-52 [10534964.001]
  • [Cites] J Palliat Care. 2000 Spring;16(1):29-34 [10802961.001]
  • [Cites] CA Cancer J Clin. 2000 Mar-Apr;50(2):123-32 [10870488.001]
  • [Cites] J Palliat Care. 2000 Autumn;16(3):16-21 [11019503.001]
  • [Cites] J Pain Symptom Manage. 2001 Mar;21(3):179-88 [11239736.001]
  • [Cites] J Palliat Med. 2001 Fall;4(3):309-14 [11596541.001]
  • [Cites] Semin Oncol. 2005 Apr;32(2):134-8 [15815957.001]
  • [Cites] J Palliat Med. 2005 Oct;8(5):1025-32 [16238515.001]
  • [Cites] Support Care Cancer. 2006 Jan;14(1):30-7 [15937688.001]
  • [Cites] J Palliat Med. 2006 Feb;9(1):137-51 [16430353.001]
  • [Cites] Crit Care Med. 2006 May;34(5):1297-310 [16540951.001]
  • [Cites] J Palliat Med. 2006 Aug;9(4):894-902 [16910804.001]
  • [Cites] Support Care Cancer. 2006 Oct;14(10):982-7 [16802127.001]
  • [Cites] Am J Hosp Palliat Care. 2007 Feb-Mar;24(1):20-8 [17347501.001]
  • [Cites] J Palliat Med. 2007 Oct;10(5):1146-52 [17985971.001]
  • [Cites] Hong Kong Med J. 2007 Dec;13(6):453-9 [18057434.001]
  • [Cites] Am J Hosp Palliat Care. 2008 Feb-Mar;25(1):24-32 [18292480.001]
  • [Cites] J Palliat Med. 2008 Oct;11(8):1094-102 [18831653.001]
  • [Cites] Cancer. 2008 Dec 1;113(11):3267-74 [18932247.001]
  • [Cites] J Natl Compr Canc Netw. 2009 Apr;7(4):436-73 [19406043.001]
  • [Cites] J Gen Intern Med. 2009 Aug;24(8):923-8 [19506972.001]
  • [Cites] Am J Hosp Palliat Care. 2009 Aug-Sep;26(4):281-7 [19357376.001]
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1412-5 [12663735.001]
  • (PMID = 19824813.001).
  • [ISSN] 1557-7740
  • [Journal-full-title] Journal of palliative medicine
  • [ISO-abbreviation] J Palliat Med
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01CA122292-01; United States / NCI NIH HHS / CA / R01CRO1CA124481; United States / NINR NIH HHS / NR / R01NR010162-01A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2883821
  •  go-up   go-down


99. Eisenbeis CF, Lesinski GB, Anghelina M, Parihar R, Valentino D, Liu J, Nadella P, Sundaram P, Young DC, Sznol M, Walker MJ, Carson WE 3rd: Phase I study of the sequential combination of interleukin-12 and interferon alfa-2b in advanced cancer: evidence for modulation of interferon signaling pathways by interleukin-12. J Clin Oncol; 2005 Dec 1;23(34):8835-44
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of the sequential combination of interleukin-12 and interferon alfa-2b in advanced cancer: evidence for modulation of interferon signaling pathways by interleukin-12.
  • PURPOSE: To evaluate the safety of sequentially administered recombinant (r) human (h) interleukin-12 (IL-12) and interferon alfa-2b (IFN-alpha-2b) in patients with advanced cancer and to determine the effects of endogenously produced IFN-gamma on Janus kinase-signal transducer and activator of transcription (Jak-STAT) signal transduction in patient peripheral-blood mononuclear cells (PBMCs).
  • PATIENTS AND METHODS: Forty-nine patients with metastatic cancer received rhIL-12 on day 1 and IFN-alpha-2b on days 2 to 6 of either a 14-day (n = 43) or a 7-day treatment cycle (n = 6).
  • RESULTS: No IL-12-or IFN-alpha-related dose-limiting toxicities were observed.
  • Optimal induction of IFN-gamma by IL-12 occurred after an IV dose of 250 ng/kg.
  • Patient PBMCs exhibited increased levels of STAT1 after IL-12 administration.
  • The peak level of IFN-gamma achieved with IL-12 therapy correlated with the peak level of intracellular STAT1 in patient PBMCs (r = 0.38, P = .021).

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16314644.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 2UO1 CA-076576-06; United States / NCI NIH HHS / CA / 5 T32 CA90223-02; United States / NCI NIH HHS / CA / CA84402; United States / NCI NIH HHS / CA / K08 CA93518; United States / NCI NIH HHS / CA / K24 CA93670; United States / NCI NIH HHS / CA / P30-CA16058
  • [Publication-type] Clinical Trial, Phase I; Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 0 / STAT1 Transcription Factor; 0 / STAT1 protein, human; 187348-17-0 / Interleukin-12; 82115-62-6 / Interferon-gamma; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


100. Reddy S, Hui D, El Osta B, de la Cruz M, Walker P, Palmer JL, Bruera E: The effect of oral methadone on the QTc interval in advanced cancer patients: a prospective pilot study. J Palliat Med; 2010 Jan;13(1):33-8
Hazardous Substances Data Bank. METHADONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effect of oral methadone on the QTc interval in advanced cancer patients: a prospective pilot study.
  • OBJECTIVE: The purpose of this study was to determine the effect of initiation of methadone on QTc interval in patients with cancer pain seen at the palliative care setting.
  • METHODS: We enrolled 100 patients with cancer in this prospective study.
  • This study supports the safety of methadone use for pain control in patients with advanced cancer in the palliative care setting.

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Intern Med. 2009 Mar 17;150(6):387-95 [19153406.001]
  • [Cites] J Palliat Care. 1996 Winter;12(4):6-9 [9019031.001]
  • [Cites] J Pain Symptom Manage. 2000 Jun;19(6):410-11 [10991645.001]
  • [Cites] Support Care Cancer. 2001 Mar;9(2):73-83 [11305074.001]
  • [Cites] J Palliat Med. 2002 Feb;5(1):127-38 [11839235.001]
  • [Cites] Ann Intern Med. 2002 Sep 17;137(6):501-4 [12230351.001]
  • [Cites] Pain. 2003 Jun;103(3):321-4 [12791438.001]
  • [Cites] Cochrane Database Syst Rev. 2003;(2):CD002209 [12804430.001]
  • [Cites] Pharmacotherapy. 2003 Jun;23(6):802-5 [12820821.001]
  • [Cites] J Pain Symptom Manage. 2003 Sep;26(3):855-9 [12967735.001]
  • [Cites] Pain. 2003 Oct;105(3):499-506 [14527710.001]
  • [Cites] J Clin Oncol. 2004 Jan 1;22(1):185-92 [14701781.001]
  • [Cites] N Engl J Med. 2004 Mar 4;350(10):1013-22 [14999113.001]
  • [Cites] J Pain Symptom Manage. 2004 Oct;28(4):301-3 [15471646.001]
  • [Cites] Am Heart J. 1973 Nov;86(5):663-8 [4743335.001]
  • [Cites] Drug Alcohol Depend. 1980 Mar;5(3):197-205 [6986247.001]
  • [Cites] Am J Med. 1984 Jul 13;77(1A):78-83 [6380281.001]
  • [Cites] JAMA. 1984 Oct 12;252(14):1905-7 [6471323.001]
  • [Cites] J Pain Symptom Manage. 1986 Fall;1(4):203-7 [3537160.001]
  • [Cites] J Pain Symptom Manage. 2008 Nov;36(5):545-52 [18440771.001]
  • [Cites] J Pain Symptom Manage. 1997 Mar;13(3):128-37 [9114631.001]
  • [Cites] J Pain Symptom Manage. 1997 Jun;13(6):356-61 [9204657.001]
  • [Cites] Postgrad Med J. 1964 Feb;40:103-5 [14122903.001]
  • [Cites] Am Fam Physician. 2005 Apr 1;71(7):1353-8 [15832538.001]
  • [Cites] J Palliat Med. 2005 Oct;8(5):1062-6 [16238524.001]
  • [Cites] Pharmacoepidemiol Drug Saf. 2005 Nov;14(11):747-53 [15918160.001]
  • [Cites] J Pain Palliat Care Pharmacother. 2005;19(4):13-24 [16431829.001]
  • [Cites] J Pain Symptom Manage. 2006 Aug;32(2):99-100 [16877171.001]
  • [Cites] J Pain Symptom Manage. 2006 Aug;32(2):180-5 [16877186.001]
  • [Cites] J Palliat Med. 2006 Aug;9(4):977-92 [16910813.001]
  • [Cites] Addiction. 2007 Feb;102(2):289-300 [17222284.001]
  • [Cites] J Opioid Manag. 2006 Sep-Oct;2(5):269-76 [17319258.001]
  • [Cites] Am Heart J. 2007 Jun;153(6):891-9 [17540188.001]
  • [Cites] Conn Med. 2007 Aug;71(7):389-97 [17879860.001]
  • [Cites] Cochrane Database Syst Rev. 2007;(4):CD003971 [17943808.001]
  • [Cites] Support Care Cancer. 2008 Jun;16(6):547-55 [18320239.001]
  • [Cites] Clin J Oncol Nurs. 2008 Aug;12(4):575-81 [18676325.001]
  • [Cites] Acta Anaesthesiol Scand. 2008 Aug;52(7):879-89 [18331375.001]
  • [CommentIn] J Palliat Med. 2010 Jun;13(6):638-9 [20597697.001]
  • (PMID = 19824814.001).
  • [ISSN] 1557-7740
  • [Journal-full-title] Journal of palliative medicine
  • [ISO-abbreviation] J Palliat Med
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01CA122292-01; United States / NCI NIH HHS / CA / R01CA124481-01; United States / NINR NIH HHS / NR / R01NR010162-01A1
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Analgesics, Opioid; UC6VBE7V1Z / Methadone
  • [Other-IDs] NLM/ PMC2939847
  •  go-up   go-down






Advertisement